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ABSTRACT

(

Peptide and protein drugs are increasingly becoming popular
with the advances in biotechnology. Although these compounds are
highly potent and display superior pharmacological profiles, there
are various barriers to their systemic delivery. Most of these barriers
are related to the properties of the proteins and peptides which
include high large molecular size, susceptibility to proteolytic
breakdown, tendency to undergo aggregation, adsorption, and
denaturation.
Most of these molecules are delivered by parenteral
administration due to the low bioavailability obtained by the oral
route. Among the noninvasive routes of drug administration, the

(

nasal route seems to be a potential alternative to parenteral
administration of peptides and proteins.
When compared to other noninvasive routes of administration,
the nasal route offers some advantages; including avoidance of the
first pass effect and enzymatic degradation in the gastrointestinal
tract; and a relatively large surface area and adequate blood flow,
resulting in rapid absorption of drugs through the nasal mucosa and
providing high patient compliance. However, there are certain factors
which could interfere with the nasal absorption of drugs such as the
method and technique of administration , and pathological conditions
of the nasal cavity.
Surprisingly few animal models have been developed and
characterized to study the basic physicochemical nature of the nasal
mucosal absorption processes, in spite of the great potential offered
11

by the intranasal route for systemic drug administration. Most of the
mechanistic and absorption screening studies have been performed
using the in situ rat nasal recirculation technique. The small nasal
cavity and nostrils of the rat restrict the evaluation of nasal
formulations such as metered sprays, powders and microspheres.
The acute nature of the perfusion technique limits its application to
small laboratory animals for economic reasons. Hence there is a need
to develop chronic perfusion techniques in large laboratory animals
which can give better representation of the nasal mucosal absorption
processes in human beings.
The objectives of this study were: (1) to develop and establish
a non-surgical perfusion technique for use with large laboratory
animals, (2) to compare the new technique with the existing
techniques, (3) to identify the study conditions to establish and
validate the animal model, ( 4) to evaluate various nasal formulations
and/or modes of administration such as sprays, microparticles usmg
the same animal model and compare with the results obtained from
perfusion studies.
Insulin was chosen as model polypeptide and the rabbit was
selected as an animal model. A randomized crossover study design
was used for evaluating the insulin effect in five rabbits. The
absorption of insulin was measured by determining blood glucose
levels using Accu chek II and ChemStrip bG strips.
A new non-surgical perfusion technique was developed and
established using the rabbit. The study conditions identified in
establishing the animal model include: the angle at which the rabbit
head is placed, the perfusion rate, the volume of the perfusate, the
111

amount of the enhancer present in the perfusate and the pH of the
solution. Spray formulations containing different levels of insulin
(1.25, 2.5, 5 and IOU/kg) and sodium taurocholate (1 %) were
evaluated in the same animal model. The nasal sprays resulted m an
immediate reduction of glucose levels. A maximum hypoglycemic
effect was observed approximately 60 minutes after administration.
As the insulin dose was increased, there was an increase in glucose
reduction. A polyacrylic acid gel formulation containing insulin
loaded microparticles (lOU/kg) resulted in a hypoglycemic effect, but
the overall effect was less when compared to the spray formulations
and s.c injection.
The apparent bioavailability was determined relative to
subcutaneously injected insulin (0.25U/kg). This bioavailability

(

increased for spray formulations as the dose of insulin was
decreased. A maximum bioavailability of 18.8% was observed for the
1.250/kg spray and the minimum bioavailability (1.58%) was
observed for the perfusion study carried out using the new
technique.

lV

ACKNOWLEDGMENT

/

I would like to express my sincere thanks to my maJor
professor, Dr. H. Zia, for his constant support, encouragement and
guidance provided to me throughout this project.
I am grateful to Dr. T. E. Needham for his scientific guidance
and financial support, without which this project wouldn't have been
a success. I also would like to express my sincere appreciation to Dr.
Lawing for his kind help and patience in analyzing the data. I am
also grateful to Dean Luzzi for providing me the financial support
during the initial stage of my graduate study at U. R. I. I would like
to thank Dr. Rodgers and Dr. Kislalioglu for their kind support. I also
would like to express my appreciation to the other faculty members
and fellow graduate students of pharmaceutics department for their
assistance provided to me during my graduate study.
Finally, I want to dedicate this work to my parents and brother
for being a constant source of encouragement and inspiration to
achieve my goals in life.

v

c

TABLE OF CONTENTS

ABSTRACT

11

ACKNOWLEDGMENT

v

TABLE OF CONTENTS

Vl

LIST OFTABLES

Vlll

x

LIST OF FIGURES
1.

IN1'RODUCTION .................................................................................................. l
1.1 Introduction ............................................................................................... 1
1.2 Nasal Physiology ....................................................................................... 5
1.3 Deposition and Clearance of Drugs from the Nasal Cavity ...... 9
1.4 Nasal Absorption of Peptides and Proteins : Physicochemical
Considerations ................................................................................................ 11

(

1.4.1 Effect of Molecular Weight.. .............................................. 11
1.4.2 Effect of Drug Concentration .. .... ................. ...................... 13
1.4.3 Effect of Dose Volume ........ ........................ .......................... 14
1.5 Pharmacokinetics of Nasal Absorption ........................................ 14
1.5.1 Factors Affecting Nasal Absorption ............................... 15
1.5 .2 Zero-order Kinetics .......................... ...................................... 17
1.5.3 First-order Kinetics .................................. ............................. 17
1.6 Enhancement of Nasal Absorption of Peptides and
Proteins ............................................................................................................. 20
1.6.1 Structural Modifications ........ .......... ... ... .. :.......................... 20
1.6.2 Formulation Design ............................................................... 21
1.6.3 Membrane Permeation Enhancers ....... ............ ...... ........ 22
1.6.3.1 Surface Active Agents .......................................... 22
1.6.3.2 Bioadhesive Agents ............................................... 30
Vl

1.6.3 .3 Vasoac ti ve Age nts ..... .... ...... ......... ..... ...... .. .......... .. 32
1.7 Animal Mod e ls Used in Evaluati on of Abso rption Studies
1. 7 .1 In Situ Absorption Model s .... .. ......... .. .. .... ... ............. ....... ... 33
1.7 .2 In vivo Absorption Model s .. .. ........ .......... .... ..... ................. 35
1.7 .3 Physical and Chemical Parameters to be Considered
in Evaluation of Absorption Models ...... ......... .. ...... ................... 38

1. 7 .3 .1 Effect of Perfusion Rate .. .. .... ... ............ ... .... ......... 3 8
1.7.3.2 Effect of Perfusate Volume .. ...... .................. ...... 38
1.7.3.3 Effect of pH ......... .... .................................................. 39
1.7 .3.4 Effect of Partition Coefficient.. .... ...... ............... .39
1.8 Insulin as a Model Drug ............ ..... ..... ....... ........... .. ............................ 40
2.

OBJECTIVES ...................................................................................................... 44

3.

MA1ERIALS AND MEIBODS ...................................................................... 47
3.1 Materials and Equipment ............ ... .... ........ .... ...... .. ........................... .47

3.2 Methods ................ .....................................................................................51
4.

RESULTS AND DISCUSSION ........................................................................ 65

4.1 Perfusion by Old Non-Surgical Technique ... ....................... ........ 65

4.2 Perfusion by New Non-Surgical technique ...... .. ....... ...... .... ........ 66
4.3 Evaluation of Nasal Formulations .... .... ..... ............... ....................... 80
4.4 Statistical Analysis ......... ................. ...................................................... 92

4.5 Comparison of Apparent Pharmacokinetic Parameters ........ 95
5.

CONCl..USIONS .............................................. ................................................. 106

6.

BIBLIOGRAPHY ......................................... ................................................... 109

Vll

LIST OF TABLES

Table 1.

Intranasal Bioavailabilities of Peptides and Proteins ...... 12

Table 2.

Blood Glucose Assay using Accu chek II to Determine
Accuracy and Precision .................. ....... ..... .................................... 61

Table 3.

Reproducibility of The Blood Glucose Assay using
Accu Chek II. ............................................... ........................................ 63

Table 4.

Glucose Concentration as a Function of Time During
Perfusion of Insulin and Buffer Solutions Using The Old
Non-Surgical Perfusion Technique ............................................ 67

Table 5.

Glucose Concentration as a Function of Time During
Perfusion of Insulin and Buffer Solutions Using The New
Non-Surgical Perfusion Technique ............................................ 71

Table 6.

Effect of Anesthetics on Blood Glucose Levels in
Rabbits ...................................................................................................76

Table 7.

Effect of Spray Formulations on Rabbit Blood Glucose
Levels ..................................................................................................... 82

Table 8.

Observed Blood Glucose Levels After Administration of
Insulin by Subcutaneous Route .................................................. 88

Table 9.

Observed Blood Glucose Levels After Administration of
Insulin by Nasal Route .................................................................... 92

Table 10.

Comparison of Mean Deviations in Blood Glucose Levels
Compared to Controls After Administration of Insulin
Spray Formulations ............ ....... ............ ........ ................................... 96

Table 11.

Comparison of Mean Deviations in Blood Glucose Levels
Compared to Controls After Administration of Insulin .... 99

viii

Table 12.

Comparison of Apparent Pharmacokinetic Parameters
After Intranasal Administration of Various Insulin
Formulations ..................................................................................... 102

lX

LIST OF FIGURES

Figure 1.

Transmission· Electron Microscopic View of Various Cell
Types in the Nasal Epithelium ....................................................... 7

Figure 2.

The Experimental Setup for In Situ Perfusion Technique
in Rat Model. ....................................................................................... 34

Figure 3.

The Top and Side Views of the Cannulation Arrangement
for In Vivo Studies in Rat Model.. .............................................. 36

Figure 4.

The Structure of Insulin Molecule ............................................ .42

Figure 5.

Schematic Diagram of the Rabbit Non-Surgical Perfusion
Technique (old) .................................................................................. 52

Figure 6.

The Experimental Setup for New Non-Surgical Perfusion
Technique in Rabbits ....................................................................... 54

(

Figure 7.

Correlation of Accuracy and Precision of the Accu Chek
Glucose Assay .......................................... ,.......................................... 60

Figure 8.

Blood Glucose as a Function of Time During Perfusion of
Insulin and Buffer Solutions Using The Old Non-Surgical
Technique ............................................................................................. 69

Figure 9.

Blood Glucose as a Function of Time During Perfusion of
Insulin and Buffer Solutions Using The New Non-Surgical
Technique ............................................................................................. 73

Figure 10. Comparison of the Reduction in Blood Glucose Using The
Two Non-Surgical Perfusion Techniques ................................ 74
Figure 11. Effect of Anesthetics on Rabbit Blood Glucose Levels ....... 78
Figure 12. Blood Glucose Concentration as a Function of Time After
Administration of Insulin Nasal Spray .................................... 84

x

(

\

Figure 13. Comparis o n of Blood Glucose Levels Afte r Administration
of Insulin by Nasal Spray and Perfusion Methods ......... .... 86
Figure 14. Comparison of Blood Glucose Red ucti o n After
Administration of Insulin by Nasal and

S.C. Routes ......... 89

Figure 15. Comparison of Blood Glucose Reduc tion After
Administration of Insulin by Spray and Gel
Formulation ......................................................................................... 93
Figure 16. Comparison of Mean Deviations in Glucose Levels From
Controls After Administration of Insulin Nasal Spray ...... 98
Figure 17. Comparison of Mean Deviations in Glucose Levels From
Controls After Administration of Insulin ............................. 101
Figure 18. Dose vs AUC for Insulin Spray Formulations in
Rabbits ................................................. ...... ....... .................................. 104

XI

1. INTRODUCTION

1.1

Introduction
With the advance of biotechnology, peptide and protein drugs

are increasingly becoming popular. However, the technology for the
manufacture of proteins and peptides has advanced far more rapidly
than our ability to deliver these molecules in appropriate and
convenient dosage forms (Sandow et al., 1987; Davis, 1989). Although
these types of compounds are highly potent and display superior
pharmacological profiles, there are a number of barriers to their
systemic deli very. Most of these barriers are related to the
properties that set proteins and peptides apart from the vast
majority of drug substances in use today. These properties include
molecular size, susceptibility to proteolytic break down, rapid plasma
clearance, peculiar dose response curves, immunogenicity,
biocompatibility and the tendency to undergo aggregation,
adsorption, and denaturation (Lee, 1988; Borchardt et al., 1989).
The oral route is the most popular means of delivering drug
molecules as it provides many advantages. However, proteins and
peptides when given orally produce very poor bioavailability,
because these molecules are easily degraded by proteolytic enzymes
in the gastrointestinal tract and are generally not well absorbed.
Currently, they are mostly delivered by parenteral administration.
However, they often have an extremely short biological half-life
when administered parenterally and repeated injections are needed.
This type of therapeutic regimen is highly risky to administer
without close medical supervision. It is often difficult for most
1

patients to accept and this leads to reduced usage and a low rate of
compliance. The commercial success of protein and peptide drugs will
depend on the development of either non-parenteral routes of
administration such as nasal, rectal, buccal, pulmonary, vaginal,
ophthalmic and transdermal or on the successful development of
other novel parenteral approaches such as implantable delivery
systems (Banga et al., 1988; Lee, 1988).
Compared to other routes, the buccal mucosa offers a large and
easily accessible area for placement of delivery systems such as
adhesive tablets, gels, and patches. However, the low bioavailability
observed for various proteins and peptides indicate that the buccal
mucosa is not very permeable to macromolecules (Lee, 1988).
Consequently, further work is required to determine whether .he
bioavailability of these molecules can be improved through the
manipulation of delivery systems.
Solutions, gels, and suppositories are conventional dosage forms
for rectal and vaginal delivery of peptides and proteins (De Boer et
al., 1990). Gel formulations seem to be the most efficient because
they offer a proper balance between retention at the site of
administration and the rate of peptide release. Though these routes
offer a promising potential for delivery of peptides and proteins, low
patient compliance is the major hurdle.
The ocular membrane can also be used for the systemic
delivery of therapeutic peptides and proteins (Banga et al., 1988).
Systemic delivery via the ocular route relies on overflow of the
instilled eye drops and nasolacrimal duct absorption. Some of the
approaches which have been found useful in enhancing the ocular
2
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absorption of peptides and proteins include use of nanoparticles,
liposomes, gels, inserts, latex systems, bioadhesives and surfactants
(Chiou et al., 1989). In addition to the permeation barrier, the
presence of peptidases in ocular tissues limit the absorption of intact
peptide and protein drugs. This route of administration is not likely
to become popular for systemic delivery since the bioavailability is
extremely low. Also, ocular tissues are extremely sensitive to foreign
substances and patient compliance could be rather low.
Compared to mucosa! routes, the transdermal route shows
greater resistance to peptide and protein absorption, primarily
because of the impermeability of the stratum corneum. Iontophoresis
is now being actively investigated to overcome this deficiency.
Results indicate limited success with significant inter-animal
variation (Lee, 1991). These contradicting results coupled with the
uncertain long-term effect of applied current on the well-being of
the skin, cast doubt on the viability of iontophoresis as a nomnvas1ve
technique to improve transdermal peptide and protein delivery.
Among the non-invasive routes of drug administration, the
nasal route seems to be a potential alternative to parenteral
administration of peptides and proteins (Lee et al., 1988; Lee, 1988;
Chien et al., 1989; Harris, 1989).
Historically, use of nasal route for drug delivery has received
the attention of mankind smce ancient times. Nasal therapy, also
called " Nasaya Karma" has been a recognized form of treatment m
the Ayurvedic system of Indian medicine for many centuries.
Psychotropic drugs and hallucinogens have been used as a nose snuff
by the Indians of South America (Chien et al., 1985). Use of the nasal

3

route to deliver peptides systemically dates back to 1922 (Chien et
al., 1985). Since then, many attempts have been made to deliver
peptides and proteins nasally. In recent years, the nasal route has
received a great deal of attention as a viable alternative to the
parenteral route for delivering proteins and peptides (Lee et
al., 1988).
When compared to other routes of administration, the nasal
route offers many advantages. In addition to its accessibility for
systemic drug delivery, the nasal cavity offers both pharmacokinetic
and pharmaceutical advantages. It offers the advantage of bypassing the metabolic elimination pathways of gastrointestinal tract
and liver and thereby significantly reducing first pass metabolism.
The nasal mucosa offers a large surface area and relatively low
enzymatic degradation resulting in the rapid absorption of drug
molecules. Thus the pharmacokinetics of intranasal administration
are characterized by rapid absorption into the systemic circulation
producing high plasma levels similar to those witnessed after

I. v.

administration. Intranasal administration 1s a convenient and easy
form of self-administered non-invasive therapy and should enjoy a
high level of patient compliance.
However, there are certain factors that limit the exploitation of
nasal route for systemic absorption of peptide and protein drugs
(Chien et al., 1989; Pontiroli et al., 1990). Rapid clearance of the
surface mucous coat in the nose shortens the time available for drug
absorption. The permeability of the nasal membrane is dependent on
the size of drug molecules. Due to their high molecular size, peptides
and proteins often need permeation enhancers to increase their
4

bioavailability. These enhancers may destroy the mucous membrane
and disrupt the nasal functions. Nasal preparations are not amenable
to formulation manipulation. Other factors that should be considered
m optimizing dosage regimens for nasal administration are, the
methods and techniques of administration and the existence of any
pathological conditions which may affect nasal function significantly.

1.2

Nasal

Physiology

The nasal passage has three physiological functions (Geurkink,
1983 ). It serves as (a) particle barrier to and a collector of inspired
dust, allergens, and microorganisms; (b) as a heat exchanger and
humidifier of air on its way to the lungs; and (c) as an organ of
olfaction.
The nasal passage which runs from the nasal vestibule to the
nasopharynx has a depth of approximate! y 12-14 cm. There are
three distinct functional zones in the nasal cavity: namely, vestibular,
respiratory, and olfactory areas (Jafek, 1983; Geurkink, 1983; Chien
et al., 1989). The vestibular area serves as a baffle system, and its
surface is covered by a common pseudostratified epithelium whose
long hairs provide the function of filtering airborne particles. The
respiratory area has a surface lined by a pseudostratified columnar
epithelium, and is normally covered by a dense layer of mucus that
is constantly moving towards the posterior apertures of the nasal
cavity by a powerful system of motile cilia. The olfactory region is
about 10 cm2 . The olfactory airway lies between the nasal septum
and the lateral wall of the main passage.

5

The anterior nares mark the beginning of the double nasal
airway, which extends from the entrance at the nostrils to the
beginning of ciliated mucosa at the anterior ends of the nasal septum
and turbanates. The main nasal passage extends backward by
approximately 6 to 8 cm to the posterior ends of the turbanates and
the arch of the septum.
The nasal mucous membrane, lining the entire nasal cavity, can
be divided into olfactory and nonolfactory epithelia. The nonolfactory
epithelium is a highly vascular tissue that is covered by
pseudostratified columnar, ciliated epithelium. The olfactory
epithelium is a pseudostratified columnar in type, and consists of
specialized olfactory cells, supporting cells, and both serous and
mucous glands.
There are two types of mucus covenng the surface of the
mucous membrane: one adheres to the tips of cilia, and the other fills
the space among the cilia. Three cell types- columnar, goblet, and
basal - make up the mucous membrane, as shown in the Figure 1.
Columnar cells, either ciliated or nonciliated are covered with
microvilli on their apical surfaces. Goblet cells secret the mucin used
in coating the epithelial layer with a protective mucus layer. Basal
cells are developing, undifferentiated columnar or goblet cells and do
not extend into the nasal cavity.
Nasal mucociliary activity is one of the most important
physiological defense mechanisms of the respiratory tract used to
protect the body against any inhaled noxious materials (Geurkink,
1983 ). The mucous blanket consists of two layers. The outer layer is

6
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Figure 1. Microscopic view of vanous cell types in the nasal
epithelium. I-nonciliated columnar cell with microvilli, II-goblet cell
with mucous granules and Golgi apparatus, III-basal cell, IV-ciliated
columnar cell with mitochondria in the apical part, OM-double
membrane, CTM-convective tissue membrane.
Source: Chien et al., 1989.
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relativel y visco us and re sts on a thin laye r of sero us fluid that tends

(

to facilitate the action of the underlying cilia. The fine particulate
matter that enters the inspired air is filtered by the process of
adhering to the mucous film.
In general, nasal mucociliary clearance carries auway
secretions backward to the nasopharynx. This material is dispatched
by a wiping action of the palate to the stomach periodically through
swallowing. However, there is an area in the anterior nares of the
inferior turbinate from which mucociliary clearance moves material
forward, and this provides a clearance of deposited foreign materials
from the body by nose blowing and wiping. Nasal clearance proceeds
at an average rate of about 1 cm/min. Thus the mucous blanket is
replaced every 10 to 15 minutes. A total of approximately 15002000 ml of mucous is produced daily, and contains 90-95% water, 12% salt, and 2-3% mucin. The functions of mucus include : (a) acts as
a retainer for substances in the nasal duct; (b) behaves as an
adhesive; (c) has water-holding capacity; (d) transports particulate
matter; (e) exhibits surface electrical activity; (f) protects the mucosa;
(g) acts as a mesh with specific permeability; and (h) allows heat
transfer. It has been reported that the nasal epithelium may be
altered- to produce excess mucus by a variety of agents, including
gases, viruses, bacteria and certain diseases such as allergic rhinitis
(Chien et al., 1989).
Pathological conditions may impau mucociliary function. Drying
of the nasal mucous membrane will cause cessation of ciliary activity
while prompt moistening will restore its normal activity. The
optimum temperature range for ciliary activity is 28 -30

8
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Hypotonic saline solutions will inhibit ciliary activity; hypertonic
saline solutions will cause it to stop. It has also been reported that
certain drugs such as adrenaline, cocaine and a number of other
drugs or chemicals will interfere with ciliary activity (Chien et al.,
1989).
Nasal secretions contain certain enzymes which cause
degradation of drugs especially peptides and proteins. These are
cytochrome P-450- dependent monooxygenase, lactate
dehydrogenase, oxidoreductase, leucine aminopeptidase and
phosphoglucomutase (Chien et al., 1989).

1.3 Deposition and Clearance of Drugs From the Nasal Cavity
The site of deposition within the nasal cavity depends upon the
delivery system used and the technique of administration applied.
The standard method of administration has been in the form of
sprays or drops being delivered using rhinyl catheters, single dose
pipettes and metered dose spray pumps (Su, 1989). The rhinyl
catheter was the first system to be introduced and has the
advantage that the catheter is graduated

for different doses as

required by the patient. The advantage of the disposable pipette is
that it is suitable for single dose administration and therefore does
not require addition of a preservative which is one of the most
singular cause of nasal irritation and allergic rhinitis in patients on
long term nasal therapy. The spray pump is simple to use and allows
multiple dosing of any given dose. The site of deposition and the rate
of clearance of the drug from nasal cavity will influence the efficacy
of the dose received by the patient.
9
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A study by Aoki & Crawley ( 1976) compared the deposition
and clearance of relatively large volumes of solution (0.1-0.75 ml)
applied as nasal sprays and drops. It was found that greater
coverage of the walls of the nasal cavity was achieved following
administration of drops. It was also observed that the clearance rates
were similar following both methods of administration and for all
dosing volumes.
The clearance of drug from the nasal cavity is a biphasic
phenomenon; a rapid initial clearance followed by slow clearance. In
another study (Hardy et al., 1984) Technetium -99m labeled human
serum albumin was administered into the human nose by a nasal
spray or nose drops. Forty percent of the dose was cleared rapidly
with average half times for clearance ranging from 6 to 9 minutes.
Following this rapid phase, clearance of the spray was much slower
than drops, because most of the spray was deposited on the
nonciliated regions, whereas the solution from the nose drops spread
more extensively over the ciliated areas of the nose.
Harris ( 1989) reported that the deposition pattern rn nasal
cavity is dependent of the mode of administration. Desmopressin
solution was administered as sprays using two types of metered
spray pumps or as drops using a rhinyle catheter or a pipette. The
pipette and rhinyle catheter deposited solution towards the rear of
the nasal cavity at the site of the nasopharynx and sprays deposited
droplets on the anterior side of the nasal cavity. Fifty percent of the
drops from the pipette and rhinyle catheter were cleared in 14 and
20 minutes whereas the 200µ 1 and 100µ l sprays were cleared in
120 and 240 minutes.
10
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Environmental conditions such as the relative humidity and
temperature, may also influence nasal clearance (A oki et al., 1976;
Hardy et al, 1985).
It is well established that pathological conditions involving
mucociliary dysfunction can greatly affect the clearance rates. For
example, Kartagener's syndrome, Sjogren's syndrome, cystic fibrosis,
and nasal polyposis have been shown to slow down the clearance
rates (Hardy et al., 1985). The common cold can cause either rapid or
slow clearance, depending on whether the subject has a 'runny nose'
or nasal congestion (Bond et al., 1984). However, Phillpotts et al.,
(1984) reported that the rate at which human interferon-a was
cleared from the nose was not substantially altered during a cold.
Therefore, it seems likely that high concentration of interferon could
be maintained in the nose during rhinovirus infection by means of an
intranasal spray.

1.4 Nasal Absorption of Peptides and Proteins Physicochemical

Considerations

There are various factors associated with peptide and proteins
which affect their transport through the biological membranes. These
include high molecular weight, concentration, volume of the dose
administered to the nasal cavity and formulation composition.

1.4.1 Effect of Molecular Weight:
Proteins and peptides have poor bioavailability after intranasal
administration because of their high molecular weight. Table 1 lists,
in order of increasing molecular weight, the bioavailabilities of a
1I

----

Table 1.

N

Intranasal bioauailabilities of proteins and peptidesa

Compound

Amino Acids
(No.)

Bioauailability
(%)

TRH
Metkephamid
Somatostatin analog
OHytocin
Oesmopressin
Buserelin
LH-RH
Nafarelin
ACTH analog
Se cretin
Glucagon
Calcitonin
GH - RH
Insulin
Beta-Interferon
Growth hormone

3
5
6
9
9
9
10
10
17
27
29
32
40
51
165
19 1

45
100
75
1
10
2.5
1.5
2
12
10
<1

a Source: Lee, 1990.

<1
<1
<1
<1
<1

senes of peptides and proteins after intranasal administration (Lee
1990). Data indicates that, for low molecular weight peptides such as
thyroid-releasing hormone and metkephamid, bioavailability can be
quite high after intranasal administration; but for larger peptides
and proteins, the nasal mucosa is relatively impermeable. Very poor
bioavailability was observed for drugs of molecular weight greater
than 1000 daltons (McMartin et al., 1987).
Maitani et al., ( 1989) investigated the nasal absorption of two
dextran derivatives, fluorescein isothiocyanate - dextran (DT) and
fluorescein isothiocyanate diethylamino ethyl dextran (DE) m the
presence of sodium glycocholate to study the influence of molecular
weight and charge using a rabbit model. The concentration of DT in
plasma decreased as the molecular weight of DT was increased. The
concentration of DE in plasma increased conversely with molecular
weight of DE (<10000). When DE & DT of same molecular weight were
given nasally, DE which carries a positively charged substituent
showed higher plasma levels when compared to DT.

1.4.2 Effect of Drug Concentration:
It was observed that the nasal absorption of L-tyrosyl-Ltyrosine was concentration dependent m the range of 2.8XI0-4 to
2. 2X 10-3M (Huang et al., 1985). Harris (1989) reported that a greater
response for desmopressin was observed after the 100 µ 1 dose than
with the 200 µ l dose given in the spray form. Su et al. (1985)
reported that the area under the curve of serum metkephamid levels
versus time increased linearly with concentration. However, Aoki et
al. (1976) reported that there was no significant effect on
13
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distribution and clearance from the nasal cavity when the
concentration of human serum albumin was changed from 3 to 30%.

1.4.3 Effect of Dose Volume:
The volume that can be administered nasally is limited. If large
volumes are administered, much of the preparation is likely to be
swallowed at the time of dosing. Harris et al. ( 1988) studied the
effect of dose volume on the nasal bioavailability of desmopressin. It
was found that the bioavailability of intranasal desmopressin from

2X50 µ L dose (20%) compared with 1X50 µ L (11 %) and lXlOO µL
(9%) spray doses. This finding suggests that an optimal dosage is
obtained by delivering drug once into each nostril. In another study
(Harris, 1989), the same group reported that

greater absorption of

desmopressin was observed from 100 µ 1 than from 200 µ 1. 200 µ 1
spray was cleared in 120 min compared to 240 min of clearance time
for 100 µl spray. However, Aoki et al. (1976) reported that no
significant difference was found when the volume was varied from

0.1 to 0.75 ml.

1.5

Pharmacokinetics

of Nasal

Absorption

Pharmacokinetics may be simply described as the
mathematical relationship that exists between the dose of a drug and
the measurable concentration in a readily accessible site in the body
(e.g., plasma or blood). The fundamental pharmacokinetic parameters
of interest are clearance, volume of distribution, half-life and
bioavailability.
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The principal pharmacokinetic rationale for employing the
nasal route is to accommodate drugs that are extensively
metabolized in the gut wall or that are subjected to extensive firstpass elimination m the liver when administered orally. Another
important reason is to provide a suitable route of administration for
drugs such as peptides or proteins, which are destroyed by the
gastrointestinal fluids, and not capable of adequate absorption into
the systemic circulation following oral administration.

1.5.1

Factors

Affecting

Nasal

Absorption:

Factors that could affect the pharmacokinetic parameters
following intranasal administration are (Colaizzi, 1985):
1. Physiology-related factors, such as
a. Vascularity
b. Speed of mucous flow
c. Presence of infection
d. Prevalent atmospheric conditions
2. Dosage form-related factors, such as
a. Concentration of drug
b. Physicochemical properties of drug
c. Density/viscosity of the formulation
d. pH of the medium
e. Pharmaceutical excipients used
f. Biocompatibility: irritancy, toxicity, etc.

3. Administration-related factors, such as
a. Volume
b. Droplet size
15

c. Spray characteristics
d. Site of deposition
e. Rate and extent of loss from the site of application
Bioavailability is defined as the fraction of the unchanged drug
reaching the site of drug action, or more usually the systemic
circulation following administration by any route. The bioavailability
of a drug after intranasal administration may be expressed in terms
of absolute absorption, Ae, determined from the area under the
curve (AUC) following the intravenous (i. v .) and intranasal (i.n.) dose
(Colaizzi, 1985).
A _ (AUC)i.n.(Dose)i.v.
e - (AUC)i.v.(Dose)i .n.

----- eq (1)

where the AUC was extrapolated to an infinite time following the
administration of a single intravenous or intranasal dose.
Ae can also be calculated from the urinary excretion data
following intravenous and intranasal administration of a single dose
of drug. It is determined from the total amount of drug excreted in
the urine in the unmetabolized form (Au
Ae

= (AU

00

00
):

)i.n.(Dose)i.v.

(AU )i. v.(Dose)i.n.
00

----- eq (2)

This equation 1s valid only when the fraction of drug dose absorbed
and excreted in the urine is the same for both intravenous and
intranasal routes.
If the body is considered to act as a single compartment, the

pharmacokinetic behavior of a drug administered by the intranasal
route may be calculated according to the following model (Colaizzi,

1985):

XIN--absorption--->XB, V--elimination---> XE
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where X1N represents the amount of drug administered to the nasal
site, Xs represents the amount of drug in the central compartment, V
is the apparent volume of distribution, and XE is the amount of drug
eliminated.

1.5.2

Zero-order

Kinetics:

In cases where the absorption of drugs from the nasal site of
administration follows zero-order kinetics, e.g., controlled delivery,
the plasma profile of the drug may be described by(Colaizzi, 1985)

dXB =Ko - KeXB
dt

----- eq (3)

rn which Ko is the zero-order absorption rate constant, and Ke is the
overall elimination rate constant. Then, the plasma concentration of
drug may be expressed as

Cp =Ko (1 - e-Ket)
Cl

----- eq (4)

where Cl is the total body clearance, and t represents any specified
time interval following the drug administration. The plasma drug
level following zero-order transnasal permeation of the drug would
increase to a steady-state plateau level (CpS S) and then begin to
decline exponentially after time tp , which is the time when there is
no more absorption of the drug from the nasal cavity.

1.5.3

First-order

Kinetics:

In cases where the absorption of drugs from the nasal site of
administration follows first-order kinetics, the plasma profile of the
drug can be described by (Colaizzi, 1985)
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----- eq (5)
where Ka is the first-order absorption rate constant, F is the fraction
of applied dose absorbed, XrN is the amount of drug administered to
the absorption site, Xs is the amount of drug in the central
compartment, Ke is the overall elimination rate constant. Then, the
plasma concentration of drug can be expressed as

Cp =

FXO K

IN a (e-Ket _ e-Kat)
V(Ka-Ke)

----- eq (6)

where XOrN is the initial drug dose applied to the site of absorption at
the time zero.
The nose is an interesting organ from kinetic point of view
because, in addition to the process of drug release, absorption, and
metabolism, it also has a carrier- and drug-translocating mechanism,
namely mucociliary clearance. A mathematical model was developed
by Gonda et al. (1990) to describe the rate processes involved in the
deposition of drugs placed in their delivery systems into the human
nasal cavity. The model contained first-order parallel and sequential
irreversible rate processes representing the convective drug and
carrier transport by fluid flow, mucociliary clearance and peristalsis,
drug release and absorption, and decomposition of the drug prior to
its appearance in the systemic circulation. The numerical values of
the parameters used were based on literature data from clearance
studies of nonabsorbable markers deposited in the human nasal
cavity. Data obtained under a variety of experimental conditions
were consistent with the model. The fitted values for DTPA
(Diethylene Triamine Penta Acetic acid) powder formulation (Gonda
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et al., 1990) were not consistent with the observed values. The effect
of bioadhesive carriers was successfully simulated by reducing the
mucociliary clearance rate constants for the transport from the the
posterior part of the nose into the gastrointestinal tract. The
simulation showed that bioadhesion improved bioavailability and
reduced the variability in absorption which might be caused by a
variable pattern of deposition in the nose. Variable bioavailability
could result from removal of the drug from the nasal cavity by
sniffing, blowing, or wiping the nose, leading to different drug
residence times in the nose. The model simulations further suggested
that drug decomposition in the nose, while lowering bioavailability,
also reduced variable absorption due to variable residence times of
the drug in the nose.
The plasma concentration following intranasal administration
shows a concentration profile that is similar to an intravenous bolus
injection (Lau et al., 1989). The rate of nasal permeation is very
rapid and it takes a very short period of time to reach the peak
plasma level. Drugs with poor oral absorption (e.g. insulin,
sulbenicillin, cephacetrile, phenol red and disodium cromoglycate)
and drugs with extensive hepatic first-pass metabolism (e.g.
progesterone, estradiol, testosterone, hydralazine, propranolol,
cocaine and nitroglycerin) can be rapidly and completely absorbed
through the nasal mucosa into the blood circulation (Chien et al.,
1989).

19

1.6 Enhancement of Nasal

Absorption

of Peptides and

Proteins
Peptides and proteins usually result in poor bioavailability
when administered nasally. The obvious reason is their relatively
large size and the impermeability of nasal membrane to these high
molecular weight compounds. Other possible reasons for low
bioavailability may be : (a) the high polarity of peptides and
proteins, (b) absorption by a carrier-mediated mechanism, (c)
hydrolysis m the nasal cavity, or (d) combinations of the above
factors.
Various approaches have been used to enhance the nasal
absorption and systemic bioavailability for peptides and proteins as
well as other drug molecules.

1.6.1

Structural

Modifications:

The physicochemical properties of drugs can be altered by
chemical modification. When administered nasally, the modified
drugs may provide improved bioavailability.
Huang et al. (l 985a), using L-tyrosine as a model amino acid,
studied the effect of structural modification on its absorption.
Acylation of the amino group on the L-tyrosine molecule had no
effect on the lipophilicity or rate of nasal absorption of the amino
acid. On the other hand, esterification of the phenolic and carboxyl
groups resulted in derivatives which are more lipophilic than Ltyrosine. The in-situ rates of nasal., absorption of the carboxylic acid
esters were significantly greater than that of L-tyrosine, whereas the
0-acyl esters were absorbed with rates similar to that of the original
20

ammo acid. It was suggested that the enhancement in the nasal
absorption of the carboxylic acid esters of L-tyrosine might be the
result of the masking of the negative charge that was on the
carboxylate moiety.

1.6.2

Formulation

Design:

The proper selection of pharmaceutical excipients m the
development of nasal formulations could enhance the formulation
stability and/or the nasal bioavailability of a drug.
Harris et al. (1989) reported that the addition of methyl
cellulose as a viscosity enhancing agent changed the pattern of
deposition and clearance of intranasal desmopressin when
administered by nasal spray and drops. The results showed that the
addition of 0.25% w/v of methyl cellulose produced a more sustained
and slower absorption. However, there was no increase in the total
bioavailability. These results were consistent with the findings of
Hussain et al. (1980) who, in a dog study, found that the addition of
methyl cellulose to a nasal solution of propranolol produced a more
sustained blood drug profile, but that the bioavailability was equal to
a solution without the viscosity enhancer. Maitani et al. (1989)
examined the effect of A vicel on the nasal absorption of Human
interferon-B in rabbits from a powder dosage form. Avicel did not
produce any significant effect on nasal absorption of Human
interferon-B from this type of product.
Nagai et al. ( 1984) studied the effect of lactose, microcrystalline
cellulose, hydroxypropyl cellulose and carbopol-sodium in powder
dosage forms for delivering insulin to the nasal cavity. The
21

absorption of insulin was fastest with microcrystalline cellulose and
was sustained when carbopol-sodium was used in the preparation.
High enhancement was observed when insulin and carbopol were
freeze-dried together prior to administration. The final powder
dosage form produced a hypoglycemia of one third of that observed
by intravenous injection assuming that the same dose of insulin was
administered.

1.6.3

Membrane

Permeation

Enhancers:

The concept of adding a component to a therapeutic drug
formulation to increase absorption and the possible mechanisms
involved has been explored extensively for transdermal delivery.
Little information is known of the physico-biochemical nature of the
nasal mucosal membrane and its influence on peptide transport. The
extent of systemic transport for a given peptide that results from
energy dependent active transport processes, versus passive
transport, is unknown and may vary given the size of the molecule,
its partition coefficient, charge characteristics and its susceptibility to
proteolysis by mucosal membranes. Various chemical components
have been used in an attempt to increase the uptake of proteins and
peptides through the nasal mucosa (Chien et al., 1989; Lee 1990).
These include the use of surfactants, bioadhesive agents and
vasoactive agents to promote nasal absorption.

1.6.3.1

Surface

Active

Agents:

The effect of surfactants on drug absorption has been the
objective of many studies. A number of these were reviewed by
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Gibaldi (1970), Gibaldi and Feldman (1970) and Lee (1990). A wide
variety of ionic and nonionic surfactants such as hydrophobic bile
salt derivatives (deoxycholate, cholate, chenodeoxycholate,
glycocholate), fusidic acid derivatives, sodium lauryl sulfate,
potassium laurate, saponin and various ether and ester derivatives of
polyoxyethylene have been shown to increase the nasal absorption of
macromolecules such as insulin (Hirai et al., 1978, 198la, 8lb, 8lc;
Pontiroli et al., 1982), calcitonin (Sandow et al., 1985), thymopentin
(Audhya et al., 1983), vasopressin (Harris et al., 1989), leutinizing
hormone releasing hormone (Fink et al., 1974 ), enkephalins (Su et al.,
1985) and human growth hormone (Baldwin et al., 1990).
Hirai et al. (1978) studied the effect of surfactants such as
saponin, sodium glycocholate and polyoxyethylene-9-lauryl ether on
nasal absorption of insulin in dogs. Insulin in the absence of the
surfactant produced slight hypoglycemia whereas the presence of
only 1% surfactant enhanced uptake of insulin. The blood glucose
level in dogs was reduced by 25-100% within 1-2 hours after
intranasal administration. Sodium glycocholate produced the
maximum effect followed by polyoxyethylene-9-lauryl ether and
saponin. The results indicated that the alteration of the nasal mucosa
by surfactants increases the permeability of mucous membrane,
which leads to enhancement in the nasal absorption of insulin.
Coadministration of insulin with 1% surfactant (such as the surfactant
of nonionic ether type, anionic or amphoteric-type, bile sats, saponin,
and surfactin) in rats was noted to produce a reduction in blood
glucose levels (Hirai et al., 198 la). The results suggested that
surfactants with an HLB value of 8-14 yield a greater reduction of
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blood glucose lev e ls. It was hypothesized that the surfactant
molecule increases nasal permeability or reduces the proteolytic
enzyme activity in the nasal mucosa, and therefore promotes the
nasal absorption of insulin. It was noted that polyoxyethylene-9lauryl ether produced a maximum hemolytic and protein-releasing
effect on the biomembrane, whereas it yielded only a slight
inhibition of the enzymatic degradation of insulin (Hirai et al.,
1981 b). On the contrary, sodium glycocholate produced a lesser
extent of both hemolytic and protein-releasing effects, but it showed
a significant inhibition of the leucine aminopeptidase activity.
Moses et al. (1983) studied the efficacy and reproducibility of
insulin given nasally to normal and diabetic subjects from an insulindeoxycholate (1 % w/v) aerosol. The formulation resulted in peak
(

serum insulin concentrations within 10 minutes after nasal
administration. The blood glucose level began to fall within 10
minutes and reached the nadir level of 54% after 30 minutes. The
nasal absorption of insulin was approximated to be 10-20% as
efficient as intravenous administration. When compared to normals,
the insulin effect was prolonged

for 5 hours in both type I and type

II diabetics although the mechanism was not clear.
In an extensive study, Gordon et al. (1985), using 40 healthy
volunteers, compared the ability of eight different bile salts
(ursodeoxycholate, chenodeoxycholate, cholate, taurocholate,
glycocholate, deoxycholate, taurodeoxycholate and
glycodeoxycholate) to enhance insulin absorption after nasal
administration . The effectiveness of the individual bile salt was
positively correlated to the hydrophobicity of the steroid nucleus, as
24

homogenates was maximally enhanced by sodium glycocholate.
However, the observed bioavailability was only 3% of as that of an
L

v. administered dose.
Mishima et al. (1987) investigated the inhibitory action of

various enhancers such as sodium caprylate, sodium caprate, sodium
laurate, sodium glycocholate on aminopeptidase activity in rats and
rabbits. It was found that sodium laurate (98%) showed the highest
inhibition of aminopeptidase activity in rat homogenate, followed by
sodium glycocholate (79%), sodium caprate (74%) and sodium
caprylate (70%). In a rabbit homogenate, sodium caprate showed 89%
inhibitory action followed by sodium caprylate (88% ), sodium laurate

(87%) and sodium glycocholate (86% ).
Aungst et al. ( 1988) compared the efficiency of the nasal,
rectal, and buccal routes for delivering insulin to rats using sodium
glycocholate as an enhancer. A five percent concentration of sodium
glycocholate was found to significantly increase insulin efficacy by
each route. The rank order was nasal > rectal > buccal > sublingual.
Nasal and rectal insulin were roughly half as effective as
intramuscular insulin.
Tengamnuay and Mitra (1990) used mixed micelles of fatty
acids and bile salt

to optimize the penetration efficacy while

m1mm1zmg any changes in membrane integrity caused by
permeation enhancers. Using in situ nasal perfusion technique, they
found that mixed micelles of sodium glycocholate and various fatty
acids m a 15:5 mM ratio were much more effective in enhancing the
nasal absorption of dipeptide [D-Arg2]Kyotorphin than the individual
adjuvants. The adjuvant activity of the mixed micelles was increased
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by increasing the ionic strength of the perfu sate and affected by the
structure of the lipid component. Oleic acid , a cis-unsaturated fatty
acid, was more effective than elaidic acid, the trans-isomer, whereas
cis-linoleic acid and trans-linolelaidic acid were equally effective.
Mixed micelles appeared to cause transient changes in the integrity
of the nasal mucosa that were fully reversible within 20-40 min
after a 60 minute exposure as judged by return of the mucosa to its
original impermeable state.
A fusidic acid derivative, sodium tauro-24,25-dihydrofusidate
(STDHF) seems to be the most promising enhancer for use in
increasing the absorption of nasally administered peptides and
proteins (Lee, 1990). Longenecker et al. (1987 ) reported that STDHF
enhanced insulin absorption in the sheep model when insulin was
delivered as nasal drops. The observed bioavailability after nasal
delivery was 16.4% relative to i.v. administration. The concentration
of STDHF and the ratio of STDHF to insulin were critical parameters m
increasing the absorption of insulin. These observations were
consistent with Hirai et al. (1981 ), who reported that enhanced
serum insulin values can be observed only when bile salts exceed the
CMC. The optimum ratio of STDHF to insulin was found to be between
5 and 10 at STD HF concentrations greater than its CMC (0.16% ).
Optimum absorption was observed at a concentration of 0.3% (w/v)
of STDHF.
In another study, Verhoef et al (1989 ) reported the promoting

ability of STDHF on nasal absorption of insulin in rats and rabbits.
The

identical fusidate formulations enhanced insulin bioavailability

from 0.9% to 5.2%

in rabbits and from 0.3 % to 18% in rats. Co27
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administration of STDHF with the trypsin inhibitor aprotinin resulted
10

an increase in insulin bioavailability in rats and a decrease

10

case

of rabbits. These results indicate that there seems to be significant
interspecies differences which can not be overlooked. Baldwin et al.
(1990) reported the nasal absorption of human growth hormone

10

three animal models. Formulations were nasally administered using a
Hamilton syringe with a polyethylene tubing (PE 10) attached. In rats,
when hGH with 0.5% STDHF

was administered in an 80-J.11 dose

volume via the nasopharyngeal route, the bioavailability was 32%.
Administration of same formulation directly into the nasal cavity
through the nares

10

a volume of 20µ l resulted in bioavailability of

17.2% (relative to i.v.). The presence of 0.5% STDHF caused

an 11-

fold increase in bioavailability of hGH in rats and in rabbits and a 21fold

increase in sheep. In all three species, the pharmacokinetic

profile observed, following nasal administration, was a pulsatile
profile. That is, the absorption of hG H was rapid followed by rapid
clearance of hGH. Glycocholate or taurocholate at 0.5% was 3 to 5
times less effective than STDHF in enhancing hGH absorption in rats.
The nasal absorption of hGH decreased as the concentration of STDHF
was reduced from 0.3 to 1.0% w/v.
Hermen et al. (1989) investigated the utility of dimethyl-betacyclodextrin in enhancing the nasal absorption of 17 beta-estradiol
rabbits and rats. High bioavailabilities of estradiol were observed
both in rabbits (95%) and rats (67%) when complexed with
cyclodextrin. In another study (Pontiroli et al., 1990), glucagon was
complexed with cyclodextrin to increase solubility and delivered
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nasally to normal volunteers. Results showed that there was no
significant in plasma glucagon levels.
A number of mechanisms have been hypothesized to explain
the activity of nasal membrane permeation enhancers (Lee et al.,
1988). For peptides and proteins that tend to aggregate in solution
(for example, insulin), solubilization of the monomeric species will
increase the molecule's thermodynamic activity and therefore its
transport across the membrane. Bile salts and STDHF have been
shown to inhibit protease activity and enhance the absorption of
drug molecules. Formation of transient hydrophillic pores in the
membrane bilayer by the bile salts also has been proposed as a
potential mechanism for enhanced protein absorption (Gordon et al.,
1985). This mechanism, however, does not explain how, once m the
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cytoplasm of the epithelial cell, the protein or peptide would be
transported out the basal side of the cell and into the capillary bed.
Surfactants such as polyoxyethylene-9-lauryl ether have been
observed to enhance nasal absorption by eroding the nasal mucous
membrane. Specific enhancers such as STDHF seem to loosen the tight
cellular junctions

and promote the nasal absorption of proteins and

peptides.
Though the presence of an enhancer usually improves the
uptake of peptides and proteins by the nasal membrane, major
concerns regarding the toxic effects and nasal membrane irritation
upon administration for long periods remain unaddressed (Martin et
al., 1978, 1981). Duchateau et al. (1986) reported that the
ciliotoxicity of the bile salts increased with increasing
\.

hydrophobicity. Dihydroxy bile salts are more toxic than trihydroxy
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bile salts. Deoxycholate was found to be extremely ciliotoxic at a
concentration of 5 mM/l. STDHF seems to be less toxic and less
irritating than bile salts (Lee et al., 1988). An ideal enhancer which
does not disrupt normal nasal functions and can enhance the uptake
of peptides and proteins through the nasal membrane has yet to be
found.

1.6.3.2

Bioadhesive

Agents:

In addition to the penetration and enzymatic barriers, rapid
clearance of the administered dose from the site of administration 1s
another hurdle limiting the absorption of peptide and protein drugs
from the nasal cavity. Nasally administered drugs are usually cleared
from from the site of deposition within 30 minutes. It is postulated
that by increasing the residence time of drug in the nasal cavity,
absorption would be increased since more time will be available for
drug to be absorbed. Residence time can be increased by
coadministering or formulating a number of different agents into the
nasal products.
Morimoto et al. (1985) demonstrated the nasal absorption
promoting activity for the bioadhesive agent, polyacrylic acid. Using
a rat model, polyacrylic acid gel was shown to enhance the biological
actions of insulin and calcitonin, both of which were inactive when
administered alone. Formulation pH ( 4.5-7 .5) did not appear to affect
insulin absorption from the gel formulation, however low viscosity
gels demonstrated a more rapid onset of insulin activity, as
measured by hypoglycemic response. However, the nasal
administration of insulin in 1% w/v carboxymethyl cellulose solution
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had no hypoglycemic effect. Harris et al. (1989) reported that the
addition of 0.25% w/v of methyl cellulose produced a more sustained
and slower absorption of desmopressin. However, there was no
increase m the total bioavailability which was consistent with the
findings of Hussain et al. (1980) who, in a dog study, found that the
addition of methyl cellulose to a nasal solution of propranolol
produced a more sustained blood levels of drug. Thus, these results
suggest that addition of a viscosity builder may sustain drug
absorption rather than increasing the bioavailability.
A similar approach involves the delivery of solid peptide
formulations designed to absorb water and to gel upon contact with
the mucosa. Good bioavailability of insulin (30%) was observed when
insulin was freeze dried together with carbopol 934 prior to nasal
administration to dogs (Nagai et al., 1984, 86). Illum et al. (1987)
studied three bioadhesive microsphere systems (albumin, starchspherex and DEAE-dextran) for nasal administration. The half life of
clearance for starch microspheres was found to be in the order of
240 minutes as compared to 15 minutes for the liquid and powder
formulations. In another study, the same group (Ilium et al., 1988)
reported that incorporation of an absorption enhancer, lysolecithin
into the starch microspheres resulted in increased uptake of
gentamicin in rats and sheep. The observed bioavailability was 50%
of the i. v. dose as compared to less than 1% for a simple nasal
solution of gentamicin. Bjork et al. (1988) investigated degradable
starch microspheres as a nasal delivery system for insulin in rats.
Insulin (0.75U/kg and 1.7U/kg) - starch microspheres administered
as a dry powder resulted in a dose-dependent decrease in blood
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glucose and a concomitant rncrease

10

serum insulin. Blood glucose

was reduced within 30-40 min by 40 % and 64% respectively using
the two aforementioned doses. The insulin peak was reached 8
minutes after dosing and the observed bioavailability was 30%.

1.7.3.3

Vasoactive

Drugs:

Olanoff and co-workers (1987) investigated a third approach to
enhance peptide delivery using what they term 'physiological
modifying agents'. These agents have vasoactive properties and exert
their action by increasing nasal mucosal blood flow. In theory, by
increasing nasal blood flow, concentrations of drug on basal side of
the nasal mucosa! membrane would remain low, increasing the
effective concentration gradient, thereby augmenting peptide
permeation across the mucosa! membrane by passive diffusion.
Agents capable of increasing nasal blood flow include histamine,
leukotriene D4, prostaglandin Ei and the beta adrenergic agonists,
isoprenaline and terbutaline. Also included in this group are agents
which promote the release of endogenous vasoactive substances such
as histamine, kinins, prostaglandins, and the vasoactive peptides. In
a clinical trial with eight normal subjects, the intranasal
administration of histamine immediately prior to desmopressin
administration increased the antidiuretic response. These results and
additional data showing an increase in nasal blood flow in the
presence of histamine suggest that peptide absorption is in part
limited by blood flow .
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1.7 Animal Models Used m

Evaluation of Nasal Absorption

Studies
Review of literature has shown that there are two types of
models which are used for evaluation of nasal absorption.

1. 7.1 In Situ Absorption

Models:

In-situ nasal perfusion studies can be used to evaluate the
nasal absorption potential of a drug and to predict the in vivo rate of
absorption. The surgical perfusion procedure was originally
developed by Hirai et al. ( 1981 a) using the rat as animal model. The
experimental set up is given in Figure 2.
In this model the rat is anesthetized and an mc1s10n is made in
the neck. The trachea is then cannulated with a polyethylene tube
and another tube is inserted through the esophagus towards the
posterior part of the nasal cavity. The nasopalatine tract which
connects the nasal cavity with the mouth is sealed with an adhesive
to prevent the drainage of the drug solution from the nasal cavity
into the mouth. The drug solution is placed in a reservoir vessel and
circulated through the nasal cavity via a peristalic pump. After
flowing through the nasal cavity, the perfusion solution passes out of
the nostrils, flows through the funnel, and returns to the reservoir
again. The extent and the rate of nasal absorption are determined,
over a period of time, by analyzing the drug concentration remaining
in the perfusing solution.
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magnetic stirring bar

Figure 2. The experimental setup for m situ perfusion technique m
rat model.
Source: Chien et al., 1989.
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1.7.2 In

Vivo

Absorption

Models:

As shown in Figure 3, the surgical procedure for in vivo studies
rn rats is similar to that described for the in-situ nasal perfusion
studies. The drug solution is administered to the nasal cavity through
the esophageal cannulation tubing or into the nostril with a syringe.
The extent and the rate of nasal absorption are determined by
analyzing drug concentrations in the plasma or in the urine over a
period of time. Since all the possible outlets in the in vivo rat model
are blocked after surgical preparation, the only possible passage for
the absorption of a drug into the systemic circulation is penetration
through the nasal mucosa. This approach is considered to provide a
well controlled animal model for screening the nasal absorption
potential of drug candidates.
A number of different animal species have been studied to
evaluate nasal absorption. These include the rat, guinea pig, rabbit,
dog, sheep, and monkey. Among these animal models, the rat model
has been used extensively for evaluation of the nasal absorption of
various drugs such as propranolol (Hussain et al., 1979; 1980);
naloxone and buprenorphine (Hussain et al., 1984 ); sulbenicillin,
cefazolin, cephacetrile, phenol red, salicylic acid, aminopyrin, and
bucolome (Hirai et al., 1981 a); insulin (Hirai et al., 1981b,198 lc;
Morimoto et al., 1985; Deurloo et al., 1989); enkephalins (Su et al.,
1985); cyclo-(-Pro-Phe-D-Trp-Lys-Thr-Phe);

horseradish peroxidase

(McMartin et al., 1987) and calcitonin (Morimoto et al., 1985). Drugs
studied nasally using the rabbit as an animal model include
progesterone and its hydroxy derivatives (Corbo et al., 1988), insulin
(Zia et al., 1989; Deurloo et al., 1989) and human interferon-beta
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Figure 3. The top and side views of the cannulation arrangement for
in vivo studies in rats.
Source: Chien et al., 1989.
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(Maitani et al., 1989). Audhya et al. (1983) used the guinea pig as an
animal model to determine the efficacy of thymopentin following
administration by various routes. The in vivo dog model was used to
evaluate nasal absorption of propranolol (Hussain et al., 1980) and
insulin (Hirai et al., 1978; Nagai et al., 1984; Longnecker et al., 1987;
Farraj et al., 1990). Sheep were used as an animal model for various
drugs such as insulin (Longenecker et al., 1987). The monkey has
been used to evaluate the nasal absorption of progesterone (Anand
Kumar et al., 1982), B-Endorphin (Jagannadha Rao et al., 186), insulin
(Anik et al., 1984 ), nafarelin acetate (Anik et al., 1984) etc.
The rat model is the most widely used model for evaluation of
the nasal absorption potential of different drug molecules because
the rat is a small animal with low cost, is easy to handle and is
inexpensive to maintain. However, the small nasal cavity and nostrils
of the rat restrict the evaluation of formulations such as metered
sprays, powders and microspheres. Because of their larger nostrils
and body size as compared to rat model; the dog, sheep and monkey
models are more suitable and practical for evaluating wider variety
of formulations and modes of administration. These animals are
larger in size, more difficult to handle, and more expensive to
maintain in the laboratory. The rabbit offers certain advantages as
an animal model. It is a laboratory animal as commonly accessible as
the rat, and provides large nostrils and increased nasal surface area
that is comparable to that of human beings. The rabbit is relatively
inexpensive, readily available, and easily maintained in the
laboratory setting. However, the nonsurvival and surgical nature of
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the perfusion technique (Hirai et al., 198 1a) re strict the use of this
approach in these species.
Mehta et al. ( 1990) developed a nonsurgical perfusion
technique and presented preliminary data using rabbit as animal
model. However more studies are necessary to establish and validate
this technique.

1. 7.3 Physical and Chemical Parameters to be Considered in
Evaluation

of Absorption

Models

1. 7.3.1 Effect of Perfusion Rate:
Huang et al. ( 1985) examined the effect of perfusion rate on
nasal absorption using the in situ nasal perfusion technique in rats.
As the perfusion rate was increased from 1.0 to 2.5 ml/min, the rate
of nasal absorption of phenobarbital increased initially and then
reached a plateau at 2 ml/min and was independent of the rate of
perfusion when pumped faster than 2 ml/min.

1.7.3.2 Effect of Perfusate

Volume:

The effect of varying the volume of the perfusion solution on
the apparent rate of absorption was studied using phenobarbital, Ltyrosine, propranolol and phenol red (Huang et al., 1985). The
apparent absorption rate constants were increased when the volume
of perfusate was increased from 3 to 20 ml. The dependency of
absorption rate constants on volume can be mathematically
described in accordance with Fick's law of diffusion:
dm

Vdc
=-DA

=

dt

dC

dt

------ eq (7)
dx
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m = amount of the drug in the perfusion solution

where

v = volume of the solution
dC/dx = Concentration gradient across the nasal
membrane with a thickness of h
D = diffusion coefficient
A = surface area of the nasal mucosa.

1.7.3.3 Effect of pH:
Hirai et al. (1978) reported that the extent and duration of
hypoglycemia induced by the nasal application of insulin depended
on the pH of the preparation. Absorption of insulin from the nasal
mucosa was enhanced significantly when it was dissolved in an acid
medium (pH 3.1) than in a neutral one. Similarly, the effect of pH on
the nasal absorption of benzoic acid (pKa=4.19) was studied by
Huang et al. (1985). As the pH of the solution was increased from 2
to 7.19, the amount absorbed was decreased from 44% to 13% (Hirai
et al., 1981). But Hussain et al. (1989) reported that the absorption of
L-tyrosine was pH independent in the range of 4-7.4.

1. 7.3.4 Effect of Partition Coefficient:
The rate and extent of absorption of a drug through a biological
membrane is influenced by its lipophilicity. Hussein et al. (1985)
studied the effect of lipophilicity on the extent of nasal absorption of
a series of barbiturates at pH 6.0, where the barbiturates (pKa=7 .6)
exist entirely in their unionized form. A forty-fold difference in the
partition coefficient of pentobarbital and barbital resulted only in a
four-fold

mcrease in the extent of absorption. Further more, it was

also observed that the nasal absorption of L-tyrosine (Hussein.,
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1989) was not significantly changed when the partition coefficient
was increased 50 times. Corbo et al. (1988) studied the nasal
delivery of progestational steroids in overiectomized rabbits. It was
found that octanol/water partition coefficient does not reflect the
partition behavior of progesterone and its derivatives in the nasal
mucosa. The systemic bioavailability was correlated well with the
nasal mucosa/buffer partition coefficient. In another study (Corbo et
al., 1990), the same group reported that nasal membrane
permeability decreased as the order of hydrophilicity of the
progestins increased.

1.8 Insulin as Model Drug
The first known description of diabetes is rn the Ebers Papyrus
of 1500 BC. An effective treatment for diabetic patients came much
later after insulin was discovered in 1921 by Banting and Best (Chien
et al., 1989a).
Diabetes is an enormous health and economic burden in the
United States and the developed countries. As of 1985, the NIH
estimated that more than six million residents of the United States
had been diagnosed with diabetes, and an additional four million
were thought to be undiagnosed. By the end of this century, the
disease could affect 20 million people in the United States alone,
where it is now responsible for about 40,000 deaths per year
(Tzagournis et al., 1989).
Insulin is a proteinous macromolecule composed of 51 ammo
acids with a molecular weight of 5,808 daltons (Figure 4). Though
insulin was discovered in 1921, it is still routinely administered in
the form of an injection. However, the use of injections throughout
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the life of a diabetic patient presents various problems including
physical and psychic pain, hypertrophy or atrophy of the
subcutaneous fat at an injection site and occasionally an allergic
reaction throughout the whole body. A tremendous amount of effort
has been directed towards developing new means of insulin delivery,
including the recent efforts to develop self-regulating insulin
delivery systems (Touitou et al., 1980; Ishida et al., 1981; Nagai et al.,
1986; Bjork et al., 1988; Farraj et al., 1990; Damge et al., 1990).
Several of these attempts were started and have either ended or are
continuing as laboratory research, with no products reaching the
market. In a recent review, Chien et al. (l 989a) discussed the vanous
approaches that have been developed for achieving systemic
delivery of insulin.
The choice of delivery routes is restricted by the molecular
dimensions of insulin and its inherent instability as a protein
molecule. Among the noninvasive routes, the nasal route seems to be
a promising alternative to injection. Attempts to deliver insulin
nasally dates back to 1922 when Woodyatt attempted to administer
insulin unsuccessfully (Chien et al., 1989a). Since then many
attempts have been made to deliver insulin nasally using a variety of
animal models. When administered alone, the bioavailability of
insulin has been found to be less than one percent because of its high
molecular weight and its susceptibility to proteolytic degradation.
When given with an enhancer or using the approaches described
above, the observed bioavailability has been increased to as high as
10-30%.
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Figure 4. The structure of insulin molecule.
Source: Chien et al., 1989a.
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Insulin was chosen as model drug for this work because it is a
well researched polypeptide, a lot of data is available in the
literature which can be served as a comparative data base for these
efforts.
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2. 0 BJECTIVES
The rich vascularity and location of the nose make it an
attractive site for the systemic absorption of drugs . Lipophilic drugs
such as propranolol (Hussain et al., 1979), progesterone (Ananda
Kumar et al., 1982), 17 JJ -estradiol (Hermens et al., 1990) etc, result
in rapid and complete absorption after intranasal administration.
Peptides and proteins, on the other hand are poorly absorbed
nasally. The bioavailability of insulin in the absence of an enhancer
was reported to be less than 1% (Hirai et al., 1978, 1981 b, 198 lc).
Similarly, the nasal bioavailability of nafarelin acetate in monkeys
was found to be only 1% of that from the intravenous administration.
While the tripeptide, L-pyro-2-2aminodipyl-L-histidyl-Lthiazolidine-4-carboxamide, although possessing fewer amino acids
than insulin and nafarelin acetate, has a poor bioavailability of 7%
(Hussain, 1985). It appears that the mechanism for nasal absorption
of drugs, especially peptides and proteins, is not fully understood. In
order to gain insight into the mechanism of nasal absorption, only
few animal models have been developed and characterized, in spite
of the great potential offered by the nasal route for systemic drug
administration. Most of the mechanistic and absorption screening
studies have been performed using the in-situ rat nasal recirculation
technique (Hirai et al., 1981a). While this technique is convenient
and reliable for in-situ studies for some drugs, it is not suitable for
in-vivo screening of formulations intended for administration by
spray devices which is the most popular means of nasal
administration. The small nasal cavity and nostrils of the rat restrict
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the evaluation of nasal formulations such as metered sprays,
powders and microspheres in this model.
Deurloo et al. ( 1989) observed significant interspecies
differences m rats and rabbits using identical nasal formulations.
STDHF at 1% (w/v) enhanced nasal insulin bioavailability from 0.9 to
5.2% and from 0.3 to 18.0% in rabbits and rats respectively.
Coadministration with the trypsin inhibitor aprotinin increased
insulin bioavailability in rats and decreased bioavailability in rabbits.
In sheep model, the observed insulin bioavailability was 16.4%
(Longenecker et al., 1987) . Baldwin et al. (1990), reported that the
presence of 0.5% STDHF enhanced nasal absorption of hGH by 11-fold
in rats and in rabbits and by 21-fold in sheep. Similarly, nasal
administration of leuprolide acetate in rats resulted in a
bioavailability of 6.0 to 40.0% when compared to

1. v.

administration

(Adjei, 1990). Intra-animal coefficient of variation of the data was 30
to 60%. The same drug when administered nasally by spray to
humans resulted in a mere 2% bioavailability. Hirai et al. (1981, 81a,
81 b) reported that in a dog study, the nasal absorption of insulin was
enhanced when it was dissolved in acid medium resulting in a
bioavailability of 25% compared with the hypoglycemic effect
following i.v. injection. However, in a human clinical study, the same
insulin solution did not produce any hypoglycemic effect and similar
results were observed with the rat model. These studies indicate that
the absorption process of macromolecules through the biological
membranes is not fully understood. Significant interspecies
differences seem to exist and no suitable perfusion technique is
available to evaluate these differences . The surgical, nonsurvival
45

nature of the rat recirculation technique limits its application only to
rats due to economic reasons and thus these animals can not act as
their own controls. Hence there is a need to develop perfusion
techniques in large laboratory animals which can give better
representation of the nasal mucosal absorption processes in human
beings. Evaluation and validation of the non-surgical perfusion
technique may address these problems.
The objectives of

this study were:

(1) to develop and establish a non-surgical perfusion technique for

use with large laboratory animals
(2) to compare the new technique with the existing perfusion
techniques
(3) to identify the study conditions to establish and validate animal
model
(4) to evaluate various nasal formulations and/or modes of
administration such as sprays, microparticles using the same model
and compare with the perfusion studies.
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3. MATERIALS AND METHODS

3.1

Materials

and

Equipment:

3.1.lMaterials:
Acepromazine maleate,

lot# 3890769

Aveco Co., Inc., Fort Dodge, Iowa 50501
Acetone, lot# 881807
Fisher Scientific, Fair Lawn, NJ 07410
Bovine insulin (25.7 I.U./mg) lot# 79F-0092
Sigma Chemical Company, St. Louis, MO 63178
Chemstrip bG test strips

lot#

252169,

Boehringer Mannheim Diagnostics, Indianapolis, IN
Cotton balls, lot# 021399,
Consumer Value stores, Woonsocket, RI 02895
Dextrose injection (5% w/v), USP, lot# 33864JT
Abbott laboratories, North Chicago, IL 60064
Ethyl alcohol-200 proof, lot# 1094,
U.S. Industrial Chemicals, Tuscola, IL 61953
Fusidic acid sodium salt, lot# 48F-0204
Sigma Chemical Company, St. Louis, MO 63178
Glucose controls lot# 30843
Boehringer Mannheim Diagnostics, Indianapolis, IN
Hydrochloric acid, lot# 026490
E.I. Dupont de Nemours & Co. (Inc.), Delaware
Ketamine hydrochloride, lot# 440105
Aveco Co., Inc., Fort Dodge, Iowa 50501
Lancets, lot# 226396,
Ulster Scientific, Inc., Highland, NY 12528
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Maltose, lot# 19F-053 l
Sigma Chemical Company, St. Louis, MO 63178
Needles, lot# Wl 1587
Becton Dickinson & Co., Rutherford, NJ 07070
Olive oil, lot# 40H-01232
Sigma Diagnostics, St. Louis, MO 63178
Palmitic acid, lot# 59F-5601
Sigma Chemical Company, St. Louis, MO 63178
Poly(acrylic acid), lot# B570080
BFGoodrich Company, Brecksville, OH 44141
Polyethylene tubing, Intramedic, PE 240, PE 260
Fisher Scientific, Fair Lawn, NJ 07410
Potassium phosphate monobasic, lot# KHTC
Mallinckrodt, Inc., Paris, Kentucky 40361
Silicone ear plug, lot# SB-30100
Santa Barbara Medco, Inc., Santa Barbara, CA 93160
Skin gel, lot# 5Kl42B,
Hollister Inc., Libertyville, IL 600048
Sodium chloride, lot# 891067
Fisher Scientific, Fair Lawn, NJ 07410
Sodium hydroxide, lot# 880519
Fisher Scientific, Fair Lawn, NJ 07410
Sodium pentobarbital, lot# 26807 AF
Abbott Laboratories, North Chicago, IL 60064
Sodium phosphate dibasic, lot# 871003,
Fisher Scientific, Fair Lawn, NJ 07410
Sodium taurocholate, lot# l l 8F-5008
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Sigma Chemical Company, St. Louis, MO 63178

3.1.2

Animals

used:

New Zealand White male rabbits, 3-5.5 kg
Millbrook farm, Amherst, MA 01004
3.1.3

Equipment:
Accu-Chek II blood glucose monitor, Model 792
Boehringer Mannheim Diagnostics, Indianapolis, IN
AutoclixTM
Bio-Dynamics, W. Germany
Constant speed and torque control unit
Cole-parmer Instrument Company, Chicago, IL
Duo Seal Vacuum pump
The Welch Scientific Company, Skokie, IL
Freeze dryer, Model 77500
Labconco Corporation, Kansas City, MO 64132
Heating mantle
Glas-Col Apparatus Co., Terre haute, IN 47802
Infusion pump, model 352
Orion research Inc.
Magnetic Stirrer, model 417
Electronic Laboratory equipment, Kansas City, MI
Mettler analytical balance, AE240 Dual range balance
Mettler Instrument Corporation, Highstown, NJ
Motomatic + Motor generator
Electro-craft Corporation , Hopkins, Minnesota
pH meter
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Markson Science, In c., Del Mar CA
POWER ST A TR variable autotransformer,
The Superior Electric Co., Bristol, Con.
Sartorius weighing balance, Model 1601MP8
Sartorius GMBH, Gottingen, Germany
Spray pump, 50 µl
Pfeiffer metered dosage systems, Princeton, NJ.
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3.2.0

Methods

3.2.1 Original Non-Surgical

Perfusion Technique (Old

Method):
Each rabbit was anesthetized using an intramuscular injection
of 75 mg/kg ketamine hydrochloride, 7 .5 mg/kg acepromazine
maleate and 12 mg/kg xylazine hydrochloride. A supplemental dose
of 50 mg of ketamine hydrochloride and 5 mg of acepromazrne
maleate was administered intraperitonially at the 60 minute interval
to maintain the anesthesia when the experiment was extended. The
original non-surgical perfusion technique was carried out according
to the method of Mehta et al. (1990). After placing the animal on its
back, a hard polyethylene tube was inserted by mouth into the
trachea to allow breathing during perfusion of the nasal cavity with
drug solution. A peroral nasal intubation cannula was prepared by
connecting two pieces of hard polyethylene tubing with a soft
polyethylene tube and folded in a shape suitable for insertion into
the nasal cavity from the mouth. Figure 5 shows this cannula and the
technique used for peroral nasal cannulation. The cannula was
inserted in the mouth and pushed into the esophagus, approximately
6 inches, and then pulled back carefully until the short end of the
cannula reached into the nasal cavity. The long end of the cannula
coming out of the mouth was connected to a perfusion pump. The
placement of the cannula was tested by infusing a small amount of
saline solution through the nasal cannula and observing saline flow
from the nostrils. Twenty ml of insulin solution was perfused at a
rate of 10 ml/hr and

the collected solution was recirculated for 3.5

hours. At the conclusion of the experiment, the cannula was removed
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Figure 5. Schematic diagram of the rabbit non-surgical perfusion
technique (old).
Source: Mehta et al., 1990.
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from the nasal cavity by pushing the cannula into the esophagus,
rotating it 900, and slowly removing from the mouth. The rabbit was
then placed on its side to remove any perfusate remaining in the
nasal cavity. Finally, the endotracheal cannula was removed and the
animal was returned to the cage after monitoring for short period.

3.2.2

New

non-Surgical

Perfusion

Technique

(New

Method):

The rabbit was anesthetized as described above. After placing
the animal on its back, a hard polyethylene tube was inserted by
mouth into the trachea in order to allow the rabbit to breathe while
the nasal cavity was being perfused by drug solution. A soft
polyethylene tube was inserted into right nostril of the rabbit. To
prevent leakage of the solution through the same nostril, a
combination of a silicone ear plug and a copolymerized polymer was
used to plug the nostril. The rabbit head was placed at an angle of
150 downwards from the horizontal plane. Figure 6 shows the
experimental set up for the new technique. The other end of the
cannula coming out of the nostril was connected to a perfusion pump
and the placement of the cannula was tested by infusing a small
amount of saline solution through the nasal cannula and observing
saline flow from the left nostril. 20 ml of insulin solution was
perfused at a rate of 10 ml/hr and

the collected solution was

recirculated for 3.5 hours. At the conclusion of the experiment, the
cannula and sealed plug were removed from the nostril and the
rabbit was then placed on its side to allow drainage of any perfusate
remaining in the nasal cavity. Finally , the endotracheal cannula was
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Figure 6. The experimental setup for new non-surgical perfusion
technique in rabbits.
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remov ed and the animal was returned to th e cage after monitoring
for a short period.

3.2.3. Study

Design:

Five New Zealand white male rabbits weighing 3.0 to 5.5 kg
were fasted for 14-16 hours prior to the experiment. The study
design used in this project was a randomized crossover with a wash
out period of at least one week between treatments.

3.2.4

Preparation

of Solutions:

(a) Perfusion Solution: Perfusion solutions were prepared by
dispersing IOU/kg of bovine insulin in 0.057M isotonic phosphate
buffer (pH 7.4 ). 0.05% w/v of sodium taurocholate was dissolved in
the perfusion solution as a permeation enhancer. A constant volume
of 20 ml solution was used throughout each perfusion study.

(b) Spray Solutions: Solutions for administration by nasal spray
were prepared by dispersing various doses of bovine insulin
(IOU/kg, 5U/kg, 2.5U/kg and 1.25U/kg) in 0.057M isotonic
phosphate buffer (pH 7.4 ). All the solutions contained 1% w/v of
sodium taurocholate as an enhancing agent. Sprays were
administered in the nasal cavity using a spray pump that delivers 50

µ 1 after each actuation. A volume of 100 µI was delivered during
each

treatment.

(c) Subcutaneous Injection Solution: Bovine insulin (0.25 U/kg)
was dispersed in 0.057M isotonic phosphate buffer (pH 7.4 ).
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3.2.5.

Preparation

of

Mucoadhesive

Microspheres:

Carbopol 934, a linear chained carboxylated poly(acrylic acid)
polymer was cross-linked with the disaccharide maltose, using a W/0
emulsification technique to form mucoadhesi ve microspheres. The
microencapsulation procedure used was same as that described by
Lewis et al. (1990). An aqueous phase consisting of 1.0 gm of
polyacrylic acid and 0.1 gm of maltose dissolved in 30 ml of purified
water was prepared. An organic medium consisting of 100 ml of
olive oil containing 0.4 gm of palmitic acid was used. Since palmitic
acid is an endogenous lipid, any residual amounts present in the
microspheres should be pharmaceutically acceptable. Both the
organic and aqueous mediums were placed in a wide mouthed bottle
ands stirred at 1600 rpm. Within several minutes a fine emulsion
was produced. An electrothermal isomantle was then placed under
the flask and the emulsion was heated to 90 - 98

oc

for 4.0 hours

until the oil appeared clear and the microspheres were cured. The
cooled mixture was poured into a large beaker containing 200 ml
acetone. The flask was washed thoroughly with a further 100 ml of
acetone. The supernatant was removed from the sedimented
particles. The microspheres were washed repeatedly with acetone
until no trace of oil could be detected. The microspheres were dried
and stored under vacuum.
Due to the high temperature involved

in

the cross-linking

process, insulin had to be incorporated into the synthesized
microsphere by swelling the particle rn a solution of drug followed
by dehydration under vacuum. This was accomplished by placing
500 mg of microspheres into a 20 ml glass vial containing 2.5 ml of
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insulin solution (1.0% w/v). The microspheres were hydrated with
insulin solution overnight and subsequently vacuum dried to obtain
a free flowing powder. In this way, insulin loaded microparticles
were produced which could be solvent activated. That is, the drug
was locked into place by the surrounding molecular chains of the
polymer, and when exposed to an environmental fluid the polymer
would swell, allowing insulin to diffuse outward. Excess drug in the
original solution will be associated with the polymer on the surface.
The polyacrylic acid aqueous gel base for insulin microparticles
was prepared by presoaking polyacrylic acid (1 % w/v) in distilled
water for 15 hours at room temperature and adjusting the pH to 6.0
by adding concentrated solution of sodium hydroxide (Morimoto et
al., 1985).

3.2.6 Administration of Insulin to Rabbits:
For perfusion studies, a constant volume of 20 ml of insulin
solution (lOU/kg) containing 0.05% w/v sodium taurocholate was
used. The perfusion was carried out for 3.5 hours at a rate of 10
ml/hr.
Spray formulations were delivered into the nasal cavity of
rabbits by spray pump. 50 J11 was delivered in each nostril and an
overall volume of 100 J1 l per rabbit was given.
For subcutaneous injection, each rabbit received 0.25 U/ kg
through the hind leg.
The insulin microparticles freeze dried together with
polyacrylic acid (IOU/kg) were suspended in l gm of polyacrylic acid
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aqueous gel base (1 % W/Y). This formulation was administered to
the nasal cavity by means of a synnge.

3.2.7

Analytical

Method:

The absorption of insulin was measured by monitoring the
blood glucose levels in the rabbits. The instrument used was an
Accu-chek II blood glucose monitor which is a battery operated
reflectance photometer that measures glucose photoelectronically rn
whole blood when used in conjunction with Chemstrip bG test strips.
The determination of glucose in whole blood with Chemstrip bG test
strips is based on the glucose oxidase/peroxidase reaction. Each
reagent strip has two test pads which contain color indicators, and
the enzymes glucose oxidase and glucose peroxidase. When whole
blood is placed on the test pads, D-glucose is oxidized to gamma- Dgluconolactone with glucose oxidase acting as a catalyst. The
hydrogen peroxide resulting from this reaction oxidizes the
indicators in the presence of peroxidase. The intensity of the colors
formed is proportional to the glucose concentration in the specimen.
When the reacted strip is placed in the instrument, the color
intensity of each test pad is evaluated by the double track optical
system and converted to a numerical blood glucose value which is
displayed on the LCD screen.
The instrument was tested initially using standard control
solutions with a concentration of 66 and 312 mg/dl as provided by
the manufacturer (Table 3).
(a) Accuracy: The accuracy of the analytical method was
determined using a standard control solution with a glucose

58

concentration of 66 mg/dl. The experiment was run six times per day
and on each of three different days. The observed mean and
standard deviation were calculated using n= 18 (Table 3 ).
If one considers the random error to be the width of the

Gaussian distribution at a specified confidence interval of 99%
(estimated by ± 2.58 x S.D), the accuracy of the method can be
obtained as the difference between the measured mean (x), and the
true value (µ) (Karnes et al., 1991). For this set of samples:
Observed value (x) = 68.3 mg/di, S.D = 2.7, n=l 8
True value (µ) = 66.0 mg/di
Accuracy = absolute value of (x-µ)
= 68.3 - 66.0 = 2.3 mg/dl
Total error (E) can be calculated as:
E = absolute value of (x-u) ± 2.58 x S.D
= (68.3-66.0) ± 2.58 x 2.7 = (-4.7 mg/dl, 9.3 mg/dl )

(b) Precision: According to the manufacturer, Accu-chek II can be
used to reliably measure blood glucose levels accurately in the range
of 20 to 500 mg/dl. To determine the accuracy of the instrument
within this range, glucose levels in blood were varied and the
observed values were compared with the predicted values. Six
samples were measured to obtain the mean and standard deviation
in each case. Initially, rabbit blood was collected and assayed for
glucose levels using Accu-chek II (Table 2). Then the glucose
concentration was increased by adding 5% dextrose solution to a
series of different levels: 152.7, 168.5, 212.0, 252.7 mg/dl. The
observed mean values (± S.D) from these samples were 152.3± 3 .4,
171. 7 ± 2.0, 208.2± 1.3 and 248.3±4.6 mg/dl respectively. To check the
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Table 2.

°'
......

Blood Glucose Assay Using Accu Chek 11 to Determine Accuracy and Precision

no

Bldl

BLOOD GLUCOSE LEUEL (mg/di)
Bld:solA2 Bld:solA2 Bld:sol83 Bldl
1:2
1: 1
1: 1

1
2
3
4
5
6

106
109
109
106
99
104

148
155
149
156
156
150

170
173
172
174
168
173

254
239
251
250
248
248

Me en 1 05.5
(SD) (3.4)

152.3
(3.4)

171. 7
(2.0)

EHpected
values -

152.7

1 68.5

Bld:P04
2:3

Bid 1

Bld:P044
2 dilution s

78
81
82
85
82
82

28
25
31
38
34
29

120
11 9
11 4
11 4
1 17
1 16

209
206
209
207
209
209

248.3
( 4.6)

81.7
(2.2)

30.8
( 4.6)

1 1 6. 7
(2.5)

208.2
( 1. 3)

252.7

-

32.7

-

21 2.0

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - 1. Blood wes collected from rabbits
2. 1 ml of 5<Jo deHtrose solution wes diluted to 25 ml with isotonic phosphate buffer
3. 2 ml of 5% deHtrose solution wes diluted to 25 ml with isotonic phosphate buffer

"'·Glucose leuel was increased to 1038.7 mg/di end then diluted with phosphate buffer.

sensitivity of the method, blood was diluted with phosphate buffer to
obtain a minimum glucose level of 32.7 mg/dl and the observed
value was 30.8± 4.6 mg/dl. Blood glucose level was increased to
1038.7 mg/dl by adding 5% dextrose solution. Since the glucose
levels higher than 500 mg/dl could not be measured, the test
solution containing 1038.7 mg/di was diluted with phosphate buffer
to bring the glucose level within the measurable range (346 mg/dl).
The observed mean value was found to be 375.2± 6.3 mg/dl. The
observed values were plotted against the expected values in Figure 7
a correlation of 0.997 was seen.

and
(c)

Reproducibility: The standard control solution with a glucose

concentration of 66.0 mg/dl was measured on each three days to
determine the reproducibility

of the assay. The results as seen in

Table 3 show that the mean observed values (± S.D) on these three
days were 67.0±2.1, 69.3±2.6 and 67.8± 1.7 mg/dl. At a 99%
confidence level, the observed glucose levels were not significantly
different from each other.

(d) Sampling: Fresh blood was collected from the ear vern of the
rabbit and tested for glucose levels at different times. In all the
studies, blood samples taken from the ear vein at -40, -20, -10, 15,
30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 300, 360
and 420 minutes after administration of insulin formulations.

3.2.8

Data

Analysis:

Quantifying absorption requues either companng plasma
insulin levels after injecting insulin, where absorption is assumed to
be complete, or comparing the response caused by the absorbed
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Table 3.

Reproducibility of The Blood Glucose Assay Using Ac cu Chek 11

no

BLOOD GLUCOSE LEUEL (mg/di)
CONTROL(low)
CONTROL(high)
dayt
day2

day3

4
5
6

309
315
320
305
309
303

64
67
69
69
68
65

70
74
68
69
69
66

66
67
66
69
69
70

Mean
(SD)

31 0.2
(5.8)

67.0
( 2. 1 )

69.3
(2.6)

67.8
( 1. 7)

EHpected
Uatues

31 2.0

66.0

66.0

66.0

1
2
3

°'

VJ

I

insulin by q ua ntifying the change in plas ma glucose concentration.
The extent of absorption or efficacy rel ativ e to injected insulin is a
primary determinant of the feasibility of the noninjectable insulin
dosage forms. In this study, the insulin efficacy was compared after
nasal administration under uniform experimental conditions. Efficacy
was estimated relative to the subcutaneous route. Blood glucose
levels were determined as a measure of insulin efficacy.

Apparent

pharmacokinetic parameters were calculated following nasal and
subcutaneous administration of insulin. The area under the curve
(AUC) was calculated based on the mean difference in the glucose
level from the controls using the trapezoidal rule. The apparent
bioavailability was calculated based on a comparison of the effect
observed when a subcutaneous injection of 0.25 U/ kg was given.

App. bioavailability = (AUCnasal x Doses.c)/(A UCs.c x Dosenasal) x 100

The SAS software package was used to analyze data obtained
during this srudy. Split-plot design and Least Significant Difference
(LSD) were used to analyze whether the drug treatments were
significant or not at 95% confidence interval (Hicks, 1982).
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4. R ESU LTS AND DISCU SS IO N

The rabbit was used as an animal model in this study as it
offers certain advantages when compared to other animal models. It
provides large nostrils and large nasal surface area that is
comparable to that of human beings. The rabbit is relatively
inexpensive, readily available, and easily maintained in the
laboratory

setting.

Insulin was used as the model drug as it provides the
challenges of a typical polypeptide in delivering through the nasal
membrane. An improved means of insulin delivery would also
alleviate the difficulties faced by the diabetic patients.
The original objective was to set up and validate an animal
model and then to proceed to evaluation of formulation development
of inatranasal drug delivery.

4.1

Perfusion by

Old

Non-Surgical Technique:

The animal model developed by Mehta et al. (1990) usrng a
non-surgical perfusion technique was selected for our use srnce the
non-surgical nature of the technique would allow the animal to act as
its own control and hence the interanimal variability could be
minimized.
Initially , perfusion studies were carried out with the rabbit as
the animal model and the performance and reproducibility of thi s
system were determined. The experiments were carried out
perfusing 20 ml of insulin solution (IOU/kg) containing 0.05 % w/v
sodium taurocholate as a permeation enhancer. The control
experiment involved perfusion of an 0.057M isotonic pho sphate
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buffe r. Th e results obtain ed dur in g this study are given

in

Tabl e -I-. It

can be see n that perfusion studies using the isotonic phosphate
buffer, resulted in an immediate increase in glucose levels with a
maximum of 297 .0± 32.5 mg/dl after 45 minutes of perfusion and
then the glucose levels were gradually reduced over a seven hour
period. In case of perfusion of insulin solution, the highest blood
glucose levels were observed at 15 minutes and then the glucose
levels were lowered gradually when compared to controls,
presumably due to the absorption of insulin into the systemic
circulation. Figure 8 shows that the lowest glucose levels (69.7 ± 8 .4
mg/dl) were observed approximately after 165 minutes of perfusion.
During this study certain difficulties were encountered. The
technique was complex and didn't provide reproducible results. The
rabbits could not be reused as the nasal cavity was often damaged
during the placement of the cannula. Thus this technique resulted m
not only variable results but also a loss of rabbits. Since the same
rabbits could not be used for crossover studies, the rabbits could not
act as their own controls. All these factors led us to develop an
improved non-surgical perfusion technique.

4.2

Perfusion

by

New

Non-Surgical

Technique:

A new non-surgical technique was developed that can be
considered relatively simple when compared to the . original
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Tobie 4.

Glucose Concentration os o Function of Time During Perfusion of Insulin ond
Buffer Solutions Using The Old Non-Surgical Perfusion Technique

Time
(min)

Blood glucose leuel (mg/di)
Phosphate buffer
Insulin solution
Mean+s.Ea
Mean+S.Eb

-40
- 30
-20
- 10
0
15
30
45
60
75
90
105
120
135

128.8±4.6
117.2±10.2
administration of anesthetics
151.3±13.4
197.0±25.8
170.3±8.5
nasal administration of insulin
265. 7±6.2
336.0±43.0
269.0± 19.3
324. 7±45.8
272.5±26.3
297 . 0±32.5
21 4.0±9.0
266.7±11.3
182.7±16.0
268.3± 1 8.1
146.2± 18.1
262. 7±9.0
262.0±6.7
105.2±12.6
99.0±8.4
241.3±14.1
83.5±3.3
245.3± 1 5.4

ar

Tobie 4.
Time
(min)

(Continued)
Bl~od

glucose leuel (mg/di)
Phosphate buffer
Insulin solution
Meon+s.Ea
Mean+S.Eb

----------

°'

00

150
165
180
210
240
300
360
420

245. 7± 19.4
245~±26.9

227.3±22.3
21 3.0±27 .2
227. 7±55.2
219.7±47.2
232.0±60.9
213.7±52.0

74.0±6.2
69.7±8.4
70.5±9.5
85.3±9.7
74.2±14.8
88.3±7.5
93.3±6.8
98.3±9.6

a .05 M isotonic phosphate buffer, pH=7.4, n = 3
b 1 OU/kg insulin + 0.05% NaTC solution, n = 4
S.E-Standard Error
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Figure 8. Blood Glucose as a Function of Time During Perfusion of
Insulin and Buffer Solutions Using The Old Non-Surgical Technique

methodology. Table 5

summanzes the results obtained by perfusing

insulin solution (1 OU/kg) containing 0.05 % sodium taurocholate. As
shown in the Figure 9, when isotonic phosphate buffer (pH 7.4) was
perfused without insulin, there was a rise in blood glucose levels
from 117.2±4.9 to 265.8±23.6 mg/dl after administration of the
anesthetics. Maximum blood glucose levels (265.8± 23.6 mg/dl) were
observed after 60 minutes. The blood glucose levels returned to
normal after 6.0 hours. When insulin solution was perfused, a similar
increase in glucose levels was observed. In this case, the perfusion of
insulin solution resulted in a gradual reduction of glucose levels. The
lowest average concentration of glucose was 88.8± 5.4 mg/dl at 240300 minutes after beginning of the perfusion.
The new technique, when compared to the old non-surgical
perfusion technique, offers many advantages. The new technique 1s
very simple and the animals can be reused without causing any
damage to the nasal cavity. Placement of the cannula is much easier
and requires less skill and/or practice than the old technique.
Moreover the results are very reproducible. The results showed that
the absorption was less in case of new technique when compared to
the ol_d technique. Figure 10 shows that the glucose reduction in case
of old technique was higher and occurred rn less time as compared to
the new technique. The higher absorption of insulin with the old
technique could be due to absorption of the drug in the throat. The
drug solution might be entering the throat due to improper
placement of the cannula. This was confirmed as the experiments
progressed by the very variable and reduced quantities of perfusate
collected from that originally added with the old technique.
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Table 5.

-J

Glucose Concentration as a function of Time during Perfusion of Insulin and
Buffer solutions Using The New Non-Surgical Perfusion Tecvrnique

Tl ME
(min)

BLOOD GLUCOSE LEUEL (mg/di)
Phosphate buffer
Insulin solution
Mean+s.Ea
Mean+s.Eb

-40
- 30
-20
-10
0
15
30
45
60
75
90
105
120
135

117.2±4.9
113.3±5.8
administration of anesthetics
151.0±12.3
143.3±2.8
189.0±12.3
188.8±13.9
nasal administration of insulin
238.6±23. 7
239.5± 12.8
260.8±27.6
253.7±16.2
252.4±21.3
249.2± 18.0
265.8±23.6
230.7±20.3
258.4±23.7
213.3±18.4
259.8±22.0
193.3±25.2
255.6±20.9
180.5±25.4
240.6± 1 5.6
153.7±24.3
225.6±14.7
143.3± 18.4

.......)

N

Tllble 5.

(Continued)

Time
(min)

Blood glucose leuel (mg/di)
Ph osphll t e bu ff er
Insulin so'lu tio n
Me11n+S.[ll
Me11n+S.Eb

150
165
180
210
240
300
360
420

220.6± 11.8
211.8±15.7
199.2±14.1
176.2±14.0
158.4± 14.5
132.0±4.8
117.8±1.8
107.8±3.7

126.0±19.2
119.2±16.8
108.8±11.3
100.5±12.8
92.0±10.2
88.8±5.4
107.8±9.2
11 6.2±9.0

a 0.05 M isotonic phosphate buffer, pH=7.4, n = 5
b 1 OU/kg insulin + O.OS°lo NaTC solution, n = 6, S.E-Standard Error
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Figure 9. Blood Glucose as a Function of Time During Perfusion of
Insulin and Buffer Solutions Using The New Non-Surgical Technique
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Figure 10. Comparison of the Reduction in Blood Glucose
Using the Two Non-Surgical Perfusion Techniques

(

Compared to the surgical technique (Hirai et al., 1981 a), the
new non-surgical perfusion technique offers many advantages. The
obvious advantage is the simplicity of technique which does not
require surgery. A second advantage is the reusability of animals
after each experiment. In previous cases where surgery is involved,
the animals had to be sacrificed resulting in not only increased cost
but also the animals can not act as their own controls. Hence a
crossover study is not feasible with the Hirai animal model. The
present technique will enable the researchers to utilize the crossover
studies to reduce inter-animal variability which often produces
discrepencies in extrapolating data in animals to humans (Adjei,
1990; Baldwin et al., 1990; Deurloo, 1989). Although the rabbit was
used as animal model in this study, it is expected that the new non surgical perfusion technique can be applied to other animals without
modification.

4.2.1

Physicochemical

Perfusion

Parameters to

be

Considered

During

Studies:

(a) Effect of Anesthetics:
During these studies, a significant increase m glucose levels was
observed after administration of the anesthetics. To better define
this observation, a control experiment was carried using two
different anesthetic combinations. Table 6 shows the effect of
anesthetics on blood glucose levels in rabbits. Sodium pentobarbital
did not exhibit any increase m blood glucose levels as evident from
Figure 11 . The combination of anesthetics used in the perfusion
studies i.e. ketamine hydrochloride , acepromazme maleate and
75

Table 6.

-....)

°'

Effect of Anesthetics on Blood Glucose Leuels in Rabbits

TIME
(min)

BLOOD GLUCOSE LEUELS (mg/di)
Controlsa
Contro1sb
Mean+S.E
Mean+S.E

-40
-30
-20
-10
15
30
45
60
75
90
105
120
135

112.3±3.7

98.3±5.2

administration of anesthetics

132.8± 1 0.9
171.1±17.3
221.1±22.6
226.6±23.4
225.1 ±23.6
229.6±22. 7
227.5±22.4
230.5±21.7
219.5±21.6
216.4±1 9.4
205.6±17.5

102.7±9.6
90.7±8.2
89.7±5.7
89.0±4.0
90.3±4.4
88.0±2.6
89.7±3.3
88.7±4.2
84.7±4.7

'

Table 6.

(Continued)

---'----------·-TIME
(min)

BLOOD GLUCOSE LEUELS (mg/di)
Controlsa
Controlsb
Mean+S.E
Mean+S.E

150
165
180
210
240
300
360
420

186.9±15.4
178.6±16.3
170.3±16.0
153.1±13.3
142.9±11.1
128.5± 1 2.2
114.5±8.0
117.6±11.5

·- - -

-.J
-.J

95.7±12.7
90.7±8.3
92.0±7.2
94.7±7.2
89.3±3.2
90.7±4.9
90.0±4.6

a Anesthetics used: Ketamine Hydrochloride, Acepromazine Maleate, and Hylazine
Hydrochloride, n=B
b Anesthetics used: Pentobarbital Sodium, n=3
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Figure 11. Effect of Anesthetics on Rabbit Blood Glucose Levels

(

xylazine hydrochloride caused a rapid n se

in

blood glucose levels

within 10 minutes after administration. Maximum glucose levels
(230.5±21.7 mg/dl) were observed at 90-120 minutes after
administration. The glucose levels returned to normal after
approximately 7 .0 hours. These results were found to be very
consistent and reproducible throughout the study in all the rabbits .
Sodium pentobarbital did not cause any change in blood glucose
levels, but could not be used in this study as it provides anesthesia
for only 45 minutes and subsequent doses may cause death to the
rabbits. For these perfusion studies, anesthesia of 4 to 4.5 hours was
required and the above mentioned combination of drugs provided
constant deep and safe anesthesia. Since the change in blood glucose
levels was consistent and predictable, the same combination of
anesthetics was used throughout the study to maintain the uniform
conditions.
The mechanism for the increase m blood glucose levels by
anesthetics is not very clear. Ketamine may be increasing plasma
epinephrine and norepinephrine levels upon injection which may
cause glycogenesis in liver cells (Katzung, 1989; Kahn et al., 1991).
Glycogenesis is the conversion of glycogen to glucose, which might be
the reason for the high glucose levels observed after injection of
anesthetics.

(b) Positioning of The Rabbit Head: The nasal cavity is like a

bowl. When perfusion is initiated, this cavity is filled with perfusate
water and the excess solution starts flowing from the left nostril. The
placement angle of the rabbit head is very critical. If the angle is too
79
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high, the head will be inclined too low , the cavity will not be filled
and lower absorption will result. If the angle is above the horizontal
plane, solution will be lost down the throat resulting an ever
decreasing volume of perfusate. In this study, the rabbit head was
placed at an angle of 140 -150 from the horizontal plane. The amount
of perfusate collected was a constant 18 to 19 ml out of 20 ml
throughout the testing which confirmed proper placement of head to
achieve maximum and reproducible absorption for each formulation.

(c) Other Factors: Other factors which would influence the
absorption of insulin from the nasal cavity are: the rate at which
insulin solution was perfused, volume of the perfusate, the time of
perfusion (Huang et al., 1985, 1985a) and the pH of the perfusate
(Hirai et al., 1978). In this study all of these parameters were held
constant to minimize the affect on the aborption of insulin. Further
studies are required to define the specific effect of each parameter.

4.3 Evaluation of Nasal

Formulations:

After establishing the experimental conditions for the new
perfusion technique and validating the rabbit as the animal model,
the se_c ond phase of this project was to evaluate the comparative
bioavailability of vanous nasal formulations of insulin using this
model. The formulations to be compared with the perfusion
technique were sprays containing different doses of insulin,
polyacrylic acid microparticles loaded with insulin, as well as a
subcutaneous injection of insulin to establish baseline parenteral
bioavailability.
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4.3.1

Spray

formulations:

Spraying a formulation into the nasal cavity is the most
popular and convenient means of delivering nasal products . For most
of the drugs designated for nasal administration , the final dosage
form will be a spray formulation. The reasons are obvious: spraying
of drugs

results in rapid absorption and in high plasma levels

similar to those observed after an i. v. injection. Sprays result in the
deposition of material on the nonciliated regions and hence the
clearance of sprays is slower compared to drops. This results in
increased absorption rates when as compared to nasal drops. Sprays
are easy to administer and very convenient thus giving increased
patient compliance. Sprays provide consistent dosing as compared to
powders and drops.
Spray formulations containing

a senes of increasing doses of

insulin were evaluated (1.25, 2.5, 5.0, 10.0 U/kg) using the rabbit
model. All the sprays contained 1% w/v of sodium taurocholate as an
enhancer. The results are summarized in Table 7 and shown in
Figure 12. Spray 3 (lOU/kg) resulted in lowest glucose levels of
3 8. 3 ± 1.15 mg/dl at 60 minutes. It was possible to replicate this
lOU/kg dose in only three rabbits because lOU/kg was found to be
fatal dose for some rabbits due to the rapid absorption of this large
amount of insulin. Spray 4 (5U/kg) gave minimum glucose levels
( 4 7.4± 9.9 mg/dl) at 60 minutes. In case the of Spray 5 (2 .5U/kg), the
lowest glucose levels 87.4± 11 . 1 mg/di were observed at 45 minutes.
The spray 6 formulation containing 1.25 U/kg of insulin resulted m
minimum levels of 102.7± 14.4 mg/dl at 90 minutes after
administration of the spray into the nasal cavity. When compared to
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THble 7.

Effect of Insulin SprHy FormulHtions on RHbbit Blood Glucose Leuels

-------------Time
(min)

00

N

-40
- 30
-20
-10
0
15
30
45
60
75
90
105
120
135

SprHy3H
107.7±6.4
125.7±0.3
145± 13.4
92.1 ±9.5
70.7±12.8
58.0± 14.6
38.3± 1.1 5
59.9±17.7
77 .2±31 .5
72.9±17.1
74.2±16.5
60.1 ±2.2

MEAN BLOOD GLUCOSE LEUELS (mg/di)
SprHy4b
SprHy5C
106.0±2.9
103.0±6.7
administration of anesthetics
125.6±4.6
120.2±4.2
143.4±4.2
152.0±11.3
nasal administration of insulin spray
105.4±6.7
144.4± 12.9
70.6±8.6
98.7±9.8
53.4±8.4
87.4±11.1
47.4±9.9
89.3±14.8
52.9±9.6
88.5±13.3
58.4±7.8
94.3± 13.4
65.4±7.9

98.4± 15.3

Sprey6d
99.6±4.1
117.4±3.7
165.2±13.0
152.2±15.9
127.3±14.9
110.0±16.1
112.4±18.4
105.9+18.3
102.7±14.4
107.0±14.3

Tobie 7.

00

VJ

(Continued)

Time
(min)

Sproy3o

150
165
180
210
240
300
360
420

75.0±16.1
60.4±4.5
75.7±14.4
75.4± 15.2
64.7±10.8
77.3±13.5
85.7±14.9
85.3± 12.2

8

b
c
d

Dose
Dose
Dose
Oose

-

MEAN BLOOD GLUCOSE LEUELS (mg/di)
Spniy4b
Spray5c

Sprny6d

71 .6±5.4

103.2±15.6

105.8±11 .5

74.1 ±6.2
71 .6±6.3
4.7±8.3
81 .3±8.4
82.3±5.4
84.5±5.1

99.1±12.1
101.5±12.0
98.5±11.9
1 06.5±5.5
99.9±5.6
111.5±7.9

109.0±13.1
105.4±10.2
105.3±10.0
98.6±6.8
101.2±11.1
108.8±17.6

1 O U/kg insulin + 1 '7o w/u sodium taurocholate, n = 3
5 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5
2.5 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5
1.25 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5
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Figure 12. Blood Glucose Concentration as a Function
of Time After Administration of Insulin Nasal Spray

the controls, as the in sulin dose was lowe red from lOU/kg to 1.25
U/kg, the insulin effect in terms of g lucose reduction was reduced
gradually.

4.3.2

Comparison of spray and

perfusion:

Figure 13 compares the results obtained using the new
perfusion technique and

a comparable nasal spray. Spray 3

containing IOU/kg of insulin resulted in an immediate reduction m
glucose levels. Minimum levels were observed at 60 minutes . The
perfusion method resulted in a gradual reduction in glucose levels.
The lowest levels were observed after 240-300 minutes. The
absorption of insulin from the nasal spray was faster compared to
the perfused insulin solution. The reasons for this may be the higher
concentration of enhancer present in the spray (lmg/100µ 1)
compared to the perfusion solution (1 Omg/20ml). It has been
reported that as the concentration of enhancer increases, drug
absorption will increase (Lee, 1990). Another reason may be that, for
the spray all the insulin (IOU/kg) was in 100 µ 1 and administered at
one time. Whereas in the case of perfusion, the same amount of
insulin (IOU/kg) was supplied to the nasal cavity in 20 ml of solution
and over a 3.5 hour period.
The exact mechanism of action of sodium taurocholate is not
known . However, it is thought to involve both solubilization of
insulin, and the direct effect of the surfactant on cell membranes
perhaps involving reverse micelle formation (Gordon et al., 1985).
The addition of bile salt is thought to result in formation of mixed
micelles of bile salt and insulin as insulin monomers (Gordon et al.,
1985). When sprayed into the nasal passages, a high transmembrane
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Figure 13. Comparison of Blood Glucose Levels After
of Insulin by Nasal Spray and Perfusion methods

Administration

concentration gradient of solubilized in sulin monomers would se rve
to drive insulin transport across the mucosal barrier. Sodium
taurocholate may also increase the membrane permeability by
loosening the intercellular junctions and/or

by increasing the

number of pores in the cell membrane (Birkett et al., 197 4 ). It is well
known that a polypeptide such as insulin is subjected to degradation
by proteolytic enzymes during passage through the mucosal
membrane. However, it has also been reported that the addition of
bile salts resulted in inhibition of the enzymatic degradation of
insulin and of the enzymatic activity of leucine aminopeptidase,
which rapidly breaks down the B-chain of insulin from the
hydrophobic N-terminal end (Hirai et al., 198lb). Never the less
additional studies are required to determine the relationship
between the enhancer concentration used rn perfusion formulations
and that utilized in spray formulations as well as the different
mechanism of providing increased absorption shown by the different
enhancers.
The bioavailability realized when testing formulations
administered by different routes should be compared to a baseline
level to evaluate the relative success of these efforts. Usually the
amount of drug absorbed nasally is quantified by comparing the
plasma levels of the drug or the biologic response after nasal
administration to those levels observed after i. v. injection. Since
insulin is usually given subcutaneously, the baseline response rn this
project was obtained by injecting insulin subcutaneously and the
nasal formulations were evaluated relative to this baseline response.
Table 8 summarizes the results obtained following subcutaneous
87

Table 8.

TIME
(min)

00
00

- 40
- 30
-20
-10
0
15
30
60
75
90
120
150
180
210
240
300
360
420
I}

Obserued Blood Glucose Leuels After Administration of Insulin by Subcutaneous
Route
BLOOD GLUCOSE LEUELS (mg/di)
Subcutaneousa
1 04.0±5.1
administration of anesthetics
11 7 .0±2.2
142.8±3.7
administration of insulin
205.6±8.2
199.6±7.5
149.4± 1 2.3
125.4± 13.2
1 06.8±9.3
77.4±6.5
68.0± 1.2
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71.6±2.6
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Figure 14. Comparison of Blood Glucose Reduction After
Administration of Insulin by Nasal and S.C. Routes

injection. The subcutaneous injection of 0.25U/kg of insulin, as
expected, resulted in slower absorption of drug from

the injection

site. As evident from Figure 14, the reduction in glucose levels after
s.c. injection, started after 15 minutes with the lowest levels of
62± 2.9 mg/dl observed approximately 180 minutes after injection.
The pattern of glucose reduction was quite different from 1OU/kg
spray. The nasal spray resulted in immediate drop in glucose levels
with minimum levels of 38.3± 1.15 mg/dl at 60 minutes after
administration. Approximately 180 minutes after administration of
s.c injection, the glucose levels returned to normal in a profile similar
to that seen in the case of the spray formulations.

4.3.3

Gel

Formulation

Containing

Insulin

Microparticles:

Although, the inclusion of bile salts in formulations could
provide a reasonable increase in the efficacy of transport and
reproducibility of dosing (Pontiroli et al., 1982; Moses et al., 1983 ),
there are serious concerns

regarding the local toxic effects and

irritation of the biological membranes by these compounds. There
are reports in the literature indicating that cholic acid derivatives
cause a breakdown of the mucous membrane structure (Martin et al.,
1976); accelerate phospholipid and protein release from membranes;
and damage intestinal mucosa, Iiposomal membranes and isolated
hepatocytes (Duchateau et al., 1986). Another problem faced in nasal
drug delivery is that all solution formulations are cleared rapidly
from the nasal cavity by the mucociliary clearance mechanism. The
mucous blanket is replaced every 10-15 minutes thereby giving
minimal contact time for absorption of the drug molecules. It is
hypothesized that by increasing the contact time or residence time,
90
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increased absorption of drugs should res ult from the nasal
membrane.

Previous researchers have used bioadhesive polymers

such as polyacrylic acid (PAA) and methyl cellulose to enhance the
absorption of drugs from nasal cavity. Polyacrylic acid has also been
used as an al tern a ti ve enhancer to promote the absorption of insulin
(Nagai et al., 1984; Morimoto et al., 1985) and

was preferred to bile

salts as it is less irritating and less toxic to the nasal membrane . In
this study, polyacrylic acid was cross-linked with maltose to obtain
microspheres. The microspheres were loaded with insulin and
freeze-dried to remove water from the system. The free flowing
microparticles thus obtained were administered nasally in a 1% w/v
poyacrylic acid gel at pH-6.0.
Polyacrylic acid microparticles loaded with insulin, when
administered nasally in a gel base to the rabbits, resulted in lower
glucose levels as compared to the controls. As evident from Figure
15, initially there was an increase in the glucose levels due to the
effect of anesthetics and then there was a gradual reduction in the
glucose levels over a period of 5.0 hours. Maximum glucose levels of
186.0±19.3 mg/dl were observed approximately 75 minutes after
administration of gel formulation (Table 9). The observed glucose
levels throughout 7 .0 hours were lower than those of the controls
indicating that the formulation was providing controlled release of
insulin.
As evident in Figure 15, the spray provides a quicker response
and a greater reduction in glucose levels. Polyacrylic acid is
bioadhesive in nature and increases the residence time of
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Table 9.

\0
N

Obserued Blood Glucose Leuels After Administration of Insulin by Nasal Route

TIME
(min)

BLOOD GLUCOSE LEUELS (mg/di)
Nasal Gel formulationa

- 40
- 30
- 20
- 10
0
15
30
45
60
75
90
120
150
180
210
240
300
360
420

114.6 ±3.9
administration of an e~ th e
131.6 ±3.2
152.8 ±7.3
administration of insulin
177.4±18.8
170.4± 1 6.4
184.2 +22.3
181.4±21.1
186.0±19.3
1 82.4±22.2
162.2±21.2
148.6±22.9
141.2±23.3
131.6±16.5
118.2±15.2
94.2±8.3
81.0±4.0
88.2±7.4

ti c s

8

Polyacrylic microparticles were loaded with insulin ( 1 OU / kg) and administered with 1 '7o
w/u polyacrylic acid gel at pH=6.0, n = 5
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Figure 15. Comparison of Blood Glucose Reduction After
Administration of Insulin by Spray and Gel Formulation

formulation in the nasal cavity and thus provides a prolonged effect
for a relatively less absorbed drug.

4.4

Statistical

analysis:

A split-plot design was as used to evaluate the drug treatment
effects on five rabbits over a time period of seven hours. Rabbit, type
of treatment (formulation/administration) and time were the three
factors used in the ANOV A procedure.
The p value obtained from the ANOV A table for the rabbit,
treatment and time factors is same, and is equal to 0.0001. There are
significant interaction effects between treatment and time and
treatment and rabbits (p=0.0001). No significant interaction effects
were observed between time and rabbits.
Least Significant Difference (LSD) test was used for paHw1se
comparisons between means of treatments, time and rabbits. All the
determinations of significance were made at the 95% confidence
level.
Controls were significantly different from perfusion (new),
spray 4 (5 U/kg), spray 5 (2.5 U/kg), spray 6 (1.25 U/kg), s.c. and
PAA micro particles (LSD=7. 9931 ). Perfusion of insulin (10 U/kg)
solution using the new technique resulted in reduction in glucose
that was significantly different from spray 4 (5 U/kg), spray 5 (2.5
U/kg), spray 6 ( 1.25 U/kg), s.c. and PAA microparticles (LSD=7 .9931 ).
Spray 4 (5 U/kg) resulted in significant glucose reduction in rabbits
compared to spray 5 (2.5 U/kg), spray 6 (1.25 U/kg), s.c. and PAA
microparticles (LSD=7 .9931). Spray 5 (2.5 U/kg) was found to be
significantly different from spray 6 (2.5 U/kg), s.c. and PAA

94

microparticles. No significant differences were observed between
spray 6 (1.25 U/kg) and s.c . injection. Glucose levels observed after
administration of PAA microparticles ( 1OU /kg) were found to be
significantly different from those observed after administration of
spray 6 ( 1.25 U/kg) and s.c. injection (0.25 U/kg).
Significant differences were observed between three rabbits
(LSD=6.7554). No significant differences were observed between the
two remaining rabbits.

4.5

Comparison

of

Apparent

Pharmacokinetic

Parameters:

The mean differences in glucose levels for rabbits receiving the
various formulations and those of the controls were used to assess
the apparent pharmacokinetic parameters. The results are
summarized in Tables 10&11 and shown visually in Figures 16&17.
Cmax is the maximum difference in glucose level from that of control.
The time at which maximum difference was observed is

tmax . The

observed values for Cmax and tmax are given in Table 12.
The time at which the maximum effect observed was relatively
same for all the spray formulations. The tmax values are 70± 10,
63±7.3, 69±9 and 75±7.5 minutes for spray 3 (10 U/kg), spray 4 (5
U/kg), spray 5 (2.5 U/kg), spray 6 (1.25 U/kg) respectively. No
significant differences in tmax values were observed for spray 4 (5
U/kg), spray 5 (2.5 U/kg) and spray 6 ( 1.25 U/kg). Subcutaneous
injection of insulin and nasal gel formulation resulted in tmax
of 120± 18.4 and 222± 62.6 minutes

values

respectively. The tmax value for

s.c. injection differed significantly from those values for the spray
formulations. The perfusion studies resulted in tmax values of
147±20.3 minutes for the new technique and 180±60.9 minutes for
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Tobie 1 0.

TIME
(min)

Comparison of Meon Deuiations in Blood Glucose Leu els Compared to Control s
After Adminitration of Insulin Spray Formulations
Mean Deuiations from Controlsa (mg/di)
Spray 3b
Spray 4c
\ pr uy 5 d

Sµni y 6e

- - - - - - - -- - --- - - - - - - - - - - --------· ---------

\0
0\

- 40
- 30
- 20
- 10
0
15
30
45
60
75
90
120

12.7.tS.3
9.2 ±3.8
administration of ane s th e ti cs
2 8 .3±2 1. 7
67.0
73.0
63.7±15.0
63.0 ±22.3
4 9 ±2 .1
administration of insulin
128.2 ±34.1
8 9.2 ±20.5
176.0±32.7
171.2 ±24.2
143.1±19.8
200.5±21.6
191.2±24.0
157.2±18.0
218.4±14.5
199.2±17.8
157.3±12.1
219.1±23.3
152.7 ± 14.8
209.2± 13.8
188.3± 1 8.3
187.4±23.3
151.5 ±21.1
214.1 ±20.8
164.0±19.9
131.0±22.7
171.1±20.1
17.5±14.5

l

11.

--------·

7 ±U. 2

22 .0 ± 13.S
4 1 .0 ±4 .0
81. 4±29 .7
114.5 ±29.8
134.6±36.9
134.2 ±39.7
135.3 ±40.3
143.1 ±39. 4
122.4±36 .4

-----

Table 10.

TIME
(min)

'° .
-...)

150
180
210
240
300
360
420

(Continued)
Mean Deviations from Controlsa (mg / di)
Spray 3b
Spray 4c
SprBy 5d

128.3±22.5
111.2±35.5
91.1±39.9
106.3±50.8
82.8±56.6
47.4±37.7
31.4±14.7

129.3 ± 18.8
110 . 7 ±22.7
92.8 ±21.7
77.9 ±21.8
63.2 ±24.6
33.5 ± 14.8
21.1 ±6.0

') 5 .2 .!: 2 3 . H
107 .5± 13 .2
6 2.9 ±20 .8
70 .4± 19 .'.j
4 6.9 ± 17 . 1
14. 2± 7.7
21.0

SprBy 6e

<Ji.6 :+: 3 1. 3
99.3 ±3 1. <J
7 8 .4±26 . 6
47 .3±2 0. 3
36.8±23 . 9
28 .4± 16.4
23.2 ±0.9

-

a
b

c
d

e

Negative UBlues were not included while determining meBn UBlues
Dose - 1 O U/kg insulin + 1 % w/u sodium tBurocholate, n = 3
Dose - 5 U/kg insulin + 1 °lo w/u sodium taurocholBte, n = 5
Dose - 2.5 U/kg insulin + 1 % w/u sodium tBurocholBte, n = 5
Dose - 1.25 U/kg insulin+ 1 % w/u sodium tBurocholBte, n = 5
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Figure 16. Comparison of Mean Deviations in Glucose Levels
From Controls After Administration of Insulin Nasal Spray
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Table 11.

Comparison of Mean Oeuiations in Blood Glucose Leuels Comp tired to
Controls After Adminitration of Insulin

TIME
(min)

Mean deuiHtions from Control~ (mg / dl)H
SubcutHneousb
Gel c
Perf11'1i o n(11 ~ 1 1 1)d
l 't! r tu'li u 11 !11 i

- - - - - -- -- - - - - -- - - - - - - - - - - - - -- --··----·- ··- - - -· --- . ----·- <\ u.5
-40
15.5 ±6.5
10.7 ±4. 4
16.3±4.2
Hdministration of ane s theti c s
- 30
- 20
20.5±18.5
56.0
38 ±17 .6
,19 . 7 ±3 5 . n
-10
I 8. 5± 4. 5
62.7±25.5
62.7±23.2
HdministrHtion of insulin formulHtion
0
119.7±47.4
54±1.0
13.0
103.5±25.5
15
128.0±48.1
47.
7
±33.5
34.0
30
76.0±40.1
127.3±36.8
39.0± 1 0.5
50.3±33.6
45
92.5±32.9
124.0±39.1
75.7±26.2
48.0±12.8
60
97.2±31.9
112.7±42. 7
100.7±6.2
79.8±11.8
115.8±32.5
75
139.0±34.0
116.3±60.2
112.7±16.6
112.2±11.5
90
116.7±62.7
81.8±31.9
137.7±5.8
1 52.0±29.5
120

"

........

0
0

Tobie 11.

(Continued)

TIME
(min)

Meon deuiations from Controlsa (mg/di)
Subcutaneousb
Gelc
Perfu si o n(n e w)d
Pe rfu sio n (ol

150
180
210
240
300
360
420

130.4±22.2
122.8±24.5
92.8±21.1
81.4±17.5
51.8±19.1
19.2±7.0
6.5±2.6

a
b
c
d
e

83.7 ±64.1
116 .5 ±69. 5
84.0 ±31.0
47.7 ±18.2
36 .7±17.6
27.0±11.1
26.5±2.5

lJ l. U± l 8. I
85 .6 ±9. 3
5 6.6 ±8 .9
62. 8± 7.7
4 1.8± 7. 2
19.2 ±8.0
18.0±13.0

:i r

1 63 .0 ~ .52 . "/

147 . 7± 15.8
12 7. 7 ±35.5
13 8.7 ±43 .6
13 1. 3±53.5
140 .7 ±67.0
1 1 5.3 ±61 .6

Negatiue ualues were not included while determining mean ualues
Dose - 0.25U/kg insulin, n = 5
Insulin microparticles (1 OU/kg) in 1 % w/u PAA gel at pH-6.0, n = 5
Perfusate (20 ml) contoined 1 OU/kg .insulin and 0.05% w/u NtiTC in buffer (pH - 7. 4 ), n = 6
Perfusi:ite (20 ml) conti:iined 1 OU/kg insulin i:ind 0.05% w/u NtiTC in buffer (pH - 7.4 ), n = 3
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Figure 17. Comparison of Mean Deviations in Glucose
Levels From Controls After Administration of Insulin
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Tobie 12.

Comporison of Apporent Phormocokinetic Porometers After lntronasal
Administrotion of Uorious Insulin Formulotions

Formulotiono
Administration

n

TmoHb

CmoHb

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- ---- -------·
S.C. injection
1 6 5. <l .!: 2"/ . 7
5
120.0 ± 1 8.4

.......
0
N

AU[b, c
- --- -----

..

%Apporent d
l! I I u El i I ti li 1 Ii t ij
--- --

--·

J2 I 5'.J.~i :t 4lJlJ9.fi

1 OU / kg Sproy

3

70.0± 10.0

224.4 !: 14 .5

4420 1.0±:7345.5

3 . -l · l

SU / kg Spniy

5

63.0±7.3

2 0 7 . <I .t:: 2 3 . 2

4 I 7 5 0 . 'J :t 4 Gll 0 . ~1

6. 11 1

2.5U/kg Sproy

5

69.0±9.0

168.8 ± 18.5

30263.9 ±2 988.0

9.41

1.25U/kg Sproy

5

75.0±9.5

154.7±39.8

29320.4±8223.5

18. 24

1 OU/kg PAA gel

5

222.0±62.6

107.0±43.2

24118.1 ±7935.4

1.8 8

Perfusion(new)e

6

147.0±20.3

116.2±18.2

20322.0±3445.3

1. 58

Perfusion (old)e

4

180.0±60.9

193.3±29.1

49894.3± 13584.0

3.88

a
b
c

Sproy formulotions contained 1 io NBTC; Perfusions contBin 0.05% NBTC
Menn ± Stondord error
ColculBted from mean differences in glucose leuels from control using the trepezoid El l
rule.

d
e

Apparent bioauailability = (AUCnosol H Ooses.c ) / (AUCs.c H Oosenas 6 1)H 1 00
1 OU/kg insulin in 20 ml phosphate buffer perfused ouer 3.5 hrs.

(

the old method. No significant difference was observed between tm ax
values observed between the two perfusion techniques . Howver the
tmax value for new perfusion technique was significantly different
from that obtained for spray formulations.
The values for Cmax showed a gradual decrease as the dose was
lowered from 10 U/kg to 1.25 U/kg. The observed values for Cmax
for spray 3 (10 U/kg), spray 4 (5 U/kg), spray 5 (2.5 U/kg), spray 6
(1.25 U/kg) were 224.4±14.5, 207.4±23.2, 168.8±18.5 and 154.7±39.8
mg/dl respectively. No significant differences were observed in Cm ax
values for the spray formulations. The observed Cmax values for the
s.c.

injection, gel formulation, the new and old perfusion techniques

were found to bel65.4±27.7, 107.3±43.2, 116.2±18.2 and 193.3±29.1
mg/dl respectively. The Cm ax value for spray 4 (5 U/kg) was found
to be significantly different from that observed for new perfusion
technique. No significant differences were observed in Cmax values
for other formulations.
The area under the curve (AUC) was calculated based on the
blood glucose levels as a function of time using trepezoidal rule. The
s.c. injection of 0.25 U/kg of insulin resulted in AUC of
32155.5±4999.6 mg/dl minute. For the spray formulations, the AUC
gradually increased from 29320.4± 8223.5 to 44201±7345.5 mg/dl
minute as the dose was increased from 1.25 U/kg to 10 U/kg. A plot
of AUC vs dose following nasal administration of the spray
formulations is given in Figure 18. The graph shows the dose to AUC
relationship after intranasal administration of insulin from spray
formulations. However, there was no proportional increase in the
AUC values when compared to the dose administered. The
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explanations for the nonlinearity observed include a saturable
binding and/or metabolism with membrane or enzyme systems . The
new perfusion technique resulted in AUC values of 20322.0± 3 445. 3
mg/dl minute. The AUC for Spray 4 (5 U/kg) was significantly
different from that observed for Spray 6 (1.25 U/kg) and new
perfusion technique. No statistically significant difference was
observed between the AUC values for Spray 4 (5 U/kg) and s.c.
injection (0.25U/kg) . The gel formulation (IOU/kg) resulted rn lower
AUC values as compared to spray 6 (1.25 U/kg) and in higher values
as compared to that found using the newperfusion
We have compared s.c. and nasal route of insulin
administration using response measurements (relative efficacy or
apparent bioavailability), rather than plasma insulin concentrations
(bioavailability). The merits of using this method are in the
simplicity of the plasma glucose determinations and that efficacy
(apparent bioavailability) is the parameter most relative to
therapeutics. Although relative efficacy could be expected to be
similar to bioavailability, this can not be assumed. Table 12
summarizes the apparent pharmacokinetic parameters obtained for
the different modes of administration. The apparent bioavailability
was calculated assuming that the effect observed for s.c. injection of
insulin was 100%.

The apparent bioavailabilities observed for spray

3 (IOU/kg), spray 4 (5U/kg), spray 5 (2.5U/kg) and spray 6
(1.25U/kg) were 3.44, 6.49, 9.41 and 18.24% respectively. The
apparent bioavailability increased gradually from spray 3 (3.44%) to
spray 6 (18.24%) . The relative absorption of insulin was higher for
1.25 U/kg spray when compared to 10 U/kg spray. The probable
105

reasons for this nonlinearity may be due to the fact that the
transport of insulin across the nasal membrane is following
saturation kinetics (Anik et al., 1984 ). In other words, the amount of
insulin that could be absorbed across the mucosal membrane is
limited and hence an increase in insulin dose did not result in
proportional increase in A UC. Insulin loaded PAA microparticles
resulted in lower bioavailability (1.88%) compared to spray
formulations, but a higher bioavailability when compared to the
perfusion studies using new technique (1.58%).
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5. CONCLUSIONS
The rabbit was used as an animal model to develop a non surgical perfusion technique. Insulin was utilized as a model
polypeptide drug . The results of this study indicated that the new
non-surgical perfusion technique can be used to evaluate the nasal
absorption potential of insulin in rabbits. The new non-surgical
perfusion technique was compared with that developed by Mehta et
al. (1990). The absorption of insulin was measured by the changes
observed in blood glucose levels. Various nasal formulations were
also evaluated using the rabbit as an animal model. The apparent
bioavailabilities for the vanous formulations/dosage forms were
determined based on the effect observed after subcutaneous
injection of insulin. The results of this investigation can be
summarized as follows:

(1) A new non-surgical perfusion technique was developed and

established using the rabbit as animal model.

(2) The new non-surgical perfusion technique was comparable to the
existing non-surgical perfusion technique. The new technique was
found to offer certain advantages compared to the old one. These
include reusability of the animal, simplicity of the technique and
reproducibility of the results. Further studies are required to
completely characterize this new technique.

(3) The study conditions needed to characterize the rabbit model
during the perfusion studies were identified. These include the angle
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at which rabbit head is placed, the perfusion rate, the volume of the
perfusate, the amount of the enhancer present in the perfusion
solution and the pH of the solution.

(4) Spray formulations containing different levels of insulin were
evaluated in the same animal model. The nasal sprays administered
by spray pump resulted in immediate reduction of glucose levels.
The maximum hypoglycemic effect was observed approximately 60
minutes after administration. As the dose was increased from 1.5
U/kg to 10 U/kg, there was an increased reduction in blood glucose
levels. However, the glucose reduction was not proportional to the
insulin dose. The PAA gel formulation containing insulin loaded
microparticles resulted in a hypoglycemic effect but the overall
effect was less compared to the spray formulations. As expected the
subcutaneous injection of insulin (0.25 U/kg) resulted in slower
absorption of insulin when compared to nasal sprays.

(5) The spray formulations tested caused a higher hypoglycemic
effect when compared to perfusion solutions most probably due to
higher amount of enhancer present in the spray formulations.

(6) The apparent bioavailability was calculated based on the AUC
values obtained from the mean differences in glucose levels from
those of the controls. The apparent bioavailability increased for
spray formulations as the dose of insulin was decreased. A maximum
apparent bioavailability of 18.8% was observed at a dose of 1.25
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(

U/kg. The lowest values were observed for the perfusion study
carried out by the new technique.

(7) A split-plot design was used

to

evaluate the treatment effects.

When compared to the controls, sprays, insulin loaded PAA
microparticles, s.c. and perfusion experiments resulted in significant
reductions in blood glucose levels at 95% confidence level.
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